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1.1. ORAL SOLID DOSAGE FORMS - A CONVENIENT DRUG DELIVERY 
SYSTEM
1 - 3
 
A drug can be administered through various routes to produce prompt 
therapeutic action. An Oral delivery is currently the gold standard in the 
pharmaceutical industry where it is regarded as the safest, most convenient, most 
economical method and having the highest patient compliance. The conventional oral 
drug delivery is the most widely utilized route of administration among all the routes. 
It remains the preferred route of administration in the discovery and development of 
new drugs. The popularity of oral route will provide patient acceptance, ease of 
administration, accurate dosing, cost effective manufacturing methods and generally 
improve the shelf life of the product. 
Oral solid forms such as Tablets and Capsules are most useful dosage forms 
for the administration of a new drug. Pharmaceutical products designed for oral 
delivery and currently available on the prescription and over the counter products are 
mostly Immediate-release type, which are designed for Immediate-release of drug for 
rapid absorption. 
1.1.1. TABLETS – Ruling dosage form since year’s overview2 
Tablet is defined as a compressed solid dosage form containing medicaments 
with or without excipients. According to the Indian Pharmacopeia Pharmaceutical 
Tablets are solid, flat or biconvex dishes, unit dosage form, prepared by compressing 
a drug or a mixture of drugs, with or without excipients. They vary in shape and 
different greatly in size and weight, depending on amount of Active Pharmaceutical 
Ingredient (API) and the intended mode of administration. It is the most popular 
dosage form and 70% of the total medicines are dispensed in the form of Tablets.  
Advantages of the Tablet dosage form  
 Tablets are unit dosage form and greatest capabilities of all oral dosage form 
for the greatest dose precision and the least content variability.  
 Less economic formulation. 
 Lighter and compact. 
 Easy to swallowing with least tendency for hang-up.  
 Modified release products can be formed easily by utilizing polymers.  
 Objectionable odour and taste can be masked by coating the Tablets.  
 Suitable for dosage form for large scale production.  
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 Greatest chemical and microbial stability over all oral dosage form.  
 Product identification is easy and rapid requiring, no additional steps when 
employing an embossed and / or monogrammed punch face.  
Disadvantages of Tablet dosage form 
 Difficult to swallow the Tablets in case of children and unconscious patients.  
 Some drugs resist compression into dense compacts, owing to amorphous 
nature, low density character.  
 Drugs with poor wetting, slow dissolution properties, may difficult to 
formulate as a Tablet that will still provide adequate or full drug 
bioavailability.  
1.1.2. Different types of Tablets  
A. Tablet ingested orally 
1. Compressed Tablets  
2. Multiple compressed Tablets  
 Compression Coated Tablets  
 Layered Tablets  
 Inlay Tablets  
3. Repeat action Tablets  
4. Delayed release Tablets  
5. Sugar coated Tablets  
6. Film coated Tablets  
7. Chewable Tablets  
8. Targeted Tablets  
B. Tablets used for oral cavity  
1. Buccal Tablets 
2. Sublingual Tablets  
3. Troches or Lozenges  
4. Dental cones  
C. Tablets administered by other route  
1. Implantation Tablets  
2. Vaginal Tablets 
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D. Tablets used to prepare solution  
1. Effervescent Tablets  
2. Hypodermic Tablets  
3. Tablet Triturates 
 
1.2. IMMEDIATE-RELEASE TABLETS
10
  
Immediate-release (IR) Tablets are those which disintegrate rapidly and get 
dissolved to release the medicaments. Immediate-release may be provided for by way 
of an appropriate pharmaceutically acceptable diluent or carrier, which diluent or 
carrier does not prolong, to an appreciable extent, the rate of drug release and/or 
absorption. This term excludes formulations which are adapted to provide for 
“modified”, “controlled”, “sustained”, “prolonged”, “extended” or “delayed” release 
of drug. 
1.2.1. DESIRED CRITERIA FOR IMMEDIATE-RELEASE DRUG 
DELIVERY SYSTEM  
 Immediate-release dosage form should dissolve or disintegrate in the stomach 
within a short period of time.  
 In the case of liquid dosage form it should be compatible with taste masking.  
 Be portable without fragility concern.  
 Have a pleasing mouth feel.  
 It should not leave minimal / no residue in the mouth after oral administration.  
 Should exhibit low sensitivity to environmental condition as humidity and 
temperature.  
 Manufactured using conventional processing and packaging equipment at low 
cost.  
 Rapid dissolution and absorption of drugs, which produces rapid onset of 
action. 
Disintegrating agents or Disintegrants  
A disintegrants are substance in a Tablet formulation that enables the Tablet to 
break up into smaller fragments upon contact with gastrointestinal fluids. Such a rapid 
rupture of the Tablet matrix increased the surface area of the Tablet particles, thereby 
increasing the rate of absorption of the active ingredient and producing the desired 
therapeutic action.  
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In the past, starch was one of the most widely used, inexpensive and effective 
disintegrant but high concentration of starch is required to bring effective 
disintegration this is overcome by using “Superdisintegrants”.  
1.2.2. SUPER DISINTEGRANTS
10, 70
 
A super disintegrant is an excipient, which is added to a Tablet or Capsule 
blend to aid in the breakup of the compacted mass when it is put into a fluid 
environment.  
Some super disintegrants are  
1. Sodium Starch Glycolate  
 It is used in concentration of 2-8% & optimum concentration is 4%.  
 Mechanism of Action: Rapid and extensive swelling with minimal 
gelling.  
2. Cross-linked Povidone (Crospovidone) 
 It is used in concentration of 2-5% of weight of Tablet. Completely 
insoluble in Water.  
 Mechanism of Action: Water wicking, swelling and possibly some 
deformation recovery rapidly disperses and swells in water, but does 
not gel even after prolonged exposure. Having greatest swelling rate 
compared to other disintegrants.  
3. Cross-linked carboxyl methyl cellulose sodium (Croscarmellose sodium):  
 Mechanism of Action: Wicking due to fibrous structure, swelling with 
minimal gelling.  
 Effective Concentrations: Upto 5%, normally 2% for direct 
compression and 3% for wet granulation process. 
1.3. COMPRESSION COATED TABLETS (CCT)
1, 7, 8, 9
 
Tablets are coated in number of ways. Coating is one of the important part in 
the formulation of pharmaceutical dosage form to achieve excellent formulation 
quality (e.g., color, texture, mouth feel, and taste masking), to provide physical and 
chemical protection to drugs in the dosage forms and to modify release 
characteristics. Coating techniques mostly used in pharmaceutical industry are 
aqueous or organic coating, which has some disadvantages. They are time consuming, 
stability for heat labile and hydrolysis of degradable drug and polluted environment 
problem. So the non-solvent coating method is introduced as alternative technique to 
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overcome these disadvantages. Non-solvent coatings have been categorized as Press 
coating, Hot melt coating, Supercritical fluid spray coating, Electrostatic coating, Dry 
powder coating. Among these techniques, Compression coating or Press coating is the 
absolute dry coating without solvent and heat use. Additionally Compression coating 
technique has no limitation for the Core Tablets and hence overcomes the adhesion 
problem found in spraying methods.  
Tablet-in-a-Tablet technology gained increased interest in the recent years for 
creating modified released products. It involves the compaction of granular materials 
around a preformed Tablet core using specially designed tableting equipment. 
Compression coating is completely dry coating process. The Compression Coated 
Tablet has two parts, internal core and surrounding coat. The Core Tablets are 
generally small in size and prepared on one turret. Then the prepared Core Tablets are 
transferred (centrally positioned) to another slightly larger die that is partially filled 
with coating powder (half of the amount), remaining coating powder is filled on the 
top of the core and compressed again resulting to form Tablet-in-a-Tablet. Mostly, the 
coat is water soluble and disintegrates easily after swallowing, in order to achieve 
Immediate-release product. This Tablet readily lend itself in to a Repeat action Tablet 
as the outer layer provides the initial dose while the inner core release the drug later 
on. But, when the core quickly releases the drug, entirely different blood level is 
achieved with the risk of over dose and toxicity occurs. To avoid Immediate-release 
of both the layers, the Core Tablet is coated with enteric polymer so that it will not 
release the drug in Stomach while, the first dose is added in outer sugar coating.  
Advantages of Tablet-in-a-Tablet technology  
 Simple and in-expensive.  
 It is useful for formulation of Tablets containing two incompatible materials 
(one in the core and the other in the coat).  
 Can be used to formulate Modified-release products such as Delayed-release 
(i.e. drug release in Intestine, Colon). 
 It is not hazardous to the environment since it does not require the use of high 
amounts of organic solvents.  
 Compression Coated Tablet (CCT) can also be used to avoid pharmacokinetic 
Drug–Drug interactions between concomitantly administered medications, 
creating a time interval between their releases into the gastrointestinal tract.  
 To protect hygroscopic, light-sensitive, oxygen labile or acid-labile drugs  
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical College Page 6 
 
    
Fig. No - 1: Compression Coated Tablet 
1.3.1. CLASSIFICATION OF COMPRESSION-COATED TABLETS BASED 
ON CORE SURFACE COATING
7
 
A compression Coated Tablet is a system in which the all surface of an inner 
core is completely surrounded by coat. These coats prevent drug release from the core 
until the polymeric coat is entirely eroded, dissolved or removed (breaking down). 
Different drug release fashion could be obtained depending on coating layer and core 
composition. 
1) Controlled release systems from Compression Coated Tablets  
Compression Coated Tablet consists of a core (rapid release or modified 
release) which is coated by compression with a coating layer which contains 
polymeric material, diluent etc., and drug. Compression Coated Tablets could be 
modulated to provide different release patterns depending on the drug distribution and 
different type of controlling polymer used in core and coat. Extended release and 
Delayed release (time, pH and microbial control) for specific region of 
gastrointestinal tract, products can be formulated by using this concept.  
2) Multiphasic release  
Multiphasic release is a delivery system designed for many diseases which 
have marked diurnal rhythms, while constant drug release does not meet the optimum 
therapeutic efficiency. In such diseases, drug concentrations are needed to vary during 
the day. Drug levels need to be highest when symptoms are most severe. In the 
system, drug is presented in coat and core as a non-uniform drug distribution matrix 
which results in biphasic drug release. With the combination of therapeutic drugs in 
one Tablet, a variety of drug release. i.e. sequential release of different drugs or multi-
phasic release of drugs is achievable. Compression Coated Tablets with multiple 
layers for desirable therapeutic use can be prepared.  
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3) Delayed release 
Delayed-release defined with lag phase and followed with release phase, is 
obtained when all surface of core is compression-coated. Pulsatile release defined by 
fast drug release after a certain lag time could be categorized within this group as 
well. Lag time for drug release could be controlled by the application of different 
polymeric coats which were differentiated with triggering factors to control drug 
release as mainly mentioned in Colonic Drug Delivery System.  
4) Time-controlled release  
A delayed-release Tablet consists of a drug core which is Compression coated 
with different polymeric (pH-independent) barriers. This delayed drug release is 
programmed for the treatment of disease that depends on circadian rhythms. The lag 
time of drug release is controlled by the compression coating, which prevents drug 
release from the core until the polymer coat is completely eroded, swollen or 
ruptured. Drug release pattern depends on the compression-coat properties.  
5) pH-controlled release 
A delayed release system using enteric polymers as a coating can provide site-
specific drug delivery especially for Colon. This system has attracted a great interest 
for improving systemic absorption of therapeutic agents susceptible to enzyme 
digestion in the upper gastrointestinal (GI) tract, while time controlled release cannot 
achieve owing to large variations in gastric emptying time.  
6) Microbial controlled release  
A delayed release system may be aimed for Colon targeting. This system is 
based on the degradation of the polymeric compression-coat by specific enzymes 
produced by entero-bacteria in the Colon. Microbial degradable polysaccharides 
containing glycosidic bonds such as alginates, arabinogalactan, arabinoxylan, 
cellulose, chitosan, amylase, chondroitin sulfate, dextran, inulin, galactomannan (guar 
gum, locust bean gum), karaya gum, laminarin, pectins, starch, tragacanth gum, 
xanthan gum and xylan, could be employed as a coat. The investigated 
polysaccharides used for Colon-specific drug delivery which could also be used in 
Compression Coated Tablet included Methoxy pectin, pectin plus HPMC.  
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1.3.2. FORMULATION CONSIDERATION OF COMPRESSION COATING 
TECHNIQUE
7
 
1) Compression coating amount  
Coating amount is the most important parameter to achieve a coating 
uniformity in compression Coated Tablets. Generally, Compression Coated Tablet 
requires a coating material which is about twice the weight of the Core Tablet or 
more, the volume must be greater than that of the core itself. If the Core Tablet 
contains low density materials, such as fats and waxes, the amount or weight of 
coating must be even greater to assure a uniform volume of coating material for 
covering the core and adhesion of core and coating. Recently, increasing the drug 
loading by decreasing the compression coat could be performed with a novel 
compression tool (one-step dry coated tablet manufacturing method; OSDRC-system) 
2) Position of core in coated layer 
The main drawback of this system is to centralize the core in the Compression 
Coated Tablets. The reproducibility of drug release from Compression Coated Tablet 
is questionable, since the faults of press-coating may occur. Examples of press-
coating fault are unequal coating, cocking and off-center. However, this drawback has 
been recently overcome by the novel compression tools (OSDRC-system) which 
placed a Core Tablet in a certain position. X-ray computed tomography as non-
invasive and rapid characterization method in online processing control for Press 
Coated Tablets (PCT). 
3) Compression force and Compressibility of materials  
The compressibility of coated Tablets is mainly depended on the coating 
material. Thus, cohesiveness and plasticity of the powder coat are needed to obtain 
satisfactory mechanical strength of the coating. The cohesiveness indicates the 
continuity of the coating around the edge of the core, which depends on its strength 
and the plasticity responses for the expansion of the core after the final Tablets are 
released from the die. The final compression force applied to prepare Compression 
Coated Tablets need to be higher than the compression force which was applied to the 
core, to ensure the adhesion between core and coat. Tablets with adhesive coating can 
be applied as core to ensure adhesion of compression coat and core.  
4) Interaction between drug and compression coat 
The interaction of drug and coating is needed to be considered especially when 
gellable coating materials are used for drug release control. Drug in Compression 
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Coated Tablets diffuses through the swollen coat. This process might enhance some 
possible interaction between drug and coat. The difference in drug release of the 
enantiomers of verapamil hydrochloride from Compression Coated Tablets containing 
chiral polymers (pectin, galactomannan and sclera glucan) as the coat has been found. 
1.3.3. FACTORS AFFECTING DRUG RELEASE IN COMPRESSION 
COATED TABLETS
7
 
1. Tablet cores 
 Drug solubility 
 Release modifiers used in Core Tablet formulation 
2. Compression coating 
 Polymer type 
 Particle size of polymer used 
 Porosity or release modifier incorporated in coat 
 Core-Coat ratio 
 Compression force 
1.3.4. RECENT TECHNOLOGIES USED IN COMPRESSION COATING 
METHOD
7
 
1. One -Step Dry Coated Tablet manufacturing method (OSDRC)  
2. Dividable Compression Coated Tablets  
3. Inlay Tablets  
1.4. TARGETED DRUG DELIVERY SYSTEM (TDDS)
4, 5
 
The concept of designing Targeted Drug Delivery System has been originated 
from the Paul Ehrlich, who was a microbiologist, proposed the idea of drug delivery 
in the form of “Magic bullet”. Selective drug targeting yet remains unachieved. 
Targeted drug delivery means accumulation of pharmacologically active moiety at 
desired target in therapeutic concentration at the same restricting its access to normal 
cellular lining. In site specific targeted drug delivery, active drug is delivered to very 
specific preselected compartments with maximum activity while reducing the 
concentration of drug to normal cells. In traditional drug delivery systems like oral 
ingestion and IV injection, the medication is distributed throughout the body through 
the systemic blood circulation. For most drugs, only a small portion of the medication 
reaches the affected organ. The drug can be targeted to intracellular sites, virus cells, 
bacteria cell and parasites using different scientific strategies have proven highly 
effective. The minimum distribution of the parent drug to the non-target cells with 
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higher and effective concentration at the targeted site certainly maximize the benefits 
of targeted drug delivery. This helps in reducing the side effects and improving the 
efficacy. 
1.4.1. PROPERTIES OF AN IDEAL TDDS
4
 
 It should be non-toxic, non-immunogenic, biocompatible, physiochemically 
stable in-vivo and in-vitro.  
 Restrict drug distribution to target cells or tissues or organs or should have 
uniform capillary distribution. 
 Controllable and predictable rate of drug release.  
 Drug release should not affect the drug distribution. 
 Therapeutic amount of drug release.  
 Drug leakage during transit must be minimal during transit. 
 Carriers used should be bio-degradable or readily eliminated from the body.  
 The preparation should be easy or reasonably simple, reproductive and cost 
effective.  
A Targeted Drug Delivery System is preferred in the following situations. 
 Pharmaceutical: drug instability and low solubility.  
 Pharmacokinetic: short half-life, large volume of distribution and poor 
absorption.  
 Pharmacodynamics: low solubility and low therapeutic index.  
1.4.2. Strategies for drug targeting
4, 6
 
1. Passive targeting  
2. Active targeting  
3. Inverse targeting  
4. Dual targeting  
5. Double targeting  
6. Combination targeting  
Active targeting can be further classified into three broad categories-  
1. First - order targeting: refers to DDS that delivers the drugs to the capillary bed 
or to the active site.  
2. Second - order targeting: refers to DDS that delivers the drug to a specific cell 
type such as the Tumour cells or Kupffer cells in lives and not to the normal cells.  
3. Third - order targeting: refers to DDS that delivers the drug to the intracellular 
site of the target cells.  
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1.5. COLON TARGETED DRUG DELIVERY SYSTEM (CTDDS) 
5, 11, 12, 13
 
Most of the conventional drug delivery systems for treating the Colon 
disorders such as Inflammatory Bowel Diseases (e.g. Irritable Bowel Syndrome, 
Ulcerative colitis, Crohn‟s disease etc.,), infectious diseases (e.g Amoebiasis) and 
Colon cancer are failing as the drugs do not reach the site of action in appropriate 
concentrations. Thus, an effective and safe therapy of these Colonic disorders, using 
site-specific drug delivery systems is a challenging task to the pharmaceutical 
technologists.  
The delivery of drugs to the Colon via gastrointestinal tract requires the 
protection of a drug from being released in stomach and small intestine. The drug 
must be released in the colon from the drug delivery system. Targeting depends on 
exploiting a unique feature of specific site and protecting the drug until it reaches to 
the site.  
Targeted drug delivery to the Colon is highly desirable for local treatment of a 
variety of bowel diseases. Inflammatory Bowel Diseases including Irritable Bowel 
Syndrome, Ulcerative Colitis and Crohn‟s disease are considered serious Colonic 
disorders. The advent of slow release technologies increases the chances for a drug to 
be released in the Colon and thus this organ has an important role to play in drug 
absorption from oral sustained release formulations.  
  Colonic drug delivery has gained increased importance not just for the 
delivery of drugs for the treatment of local diseases associated with the Colon but also 
for its potential for the delivery of proteins and therapeutic peptides. 
1.5.1. Advantages of CTDDS
5
 
 Local treatment requires small drug quantities than quantity required for 
conventional dosage forms 
 Frequency can be reduced, hence lower the cost of expensive drug 
 Side effects and interactions can be minimized 
 The colon is the attractive site of poorly absorbed drugs, so the bioavailability 
can be increased by colon targeting 
 Reduces gastric irritation caused by many drugs 
 Bypasses initial first pass metabolism 
 Improved patient compliance 
 It has longer retention time and appears highly responsive to agents that 
enhance the absorption of poorly absorbed drugs 
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 It has low hostile environment, less peptidase activity so peptides, oral 
vaccines, insulin, growth hormones can be given through this route. 
1.5.2. Limitations of CTDDS
5
  
 One challenge in the development of Colon-specific Drug Delivery Systems is 
to establish an appropriate in-vitro dissolution testing method to evaluate the 
designed system. This is due to the rationale after a Colon-specific Drug 
Delivery System is quite diverse. 
 The targeting of drugs to the Colon is very complicated. Due to its location in 
the distal part of the alimentary canal, the Colon is particularly difficult to 
access. In addition to that the wide range of pH values and different enzymes 
present throughout the gastrointestinal tract, through which the dosage form 
has to travel before reaching the target site, further complicate the reliability 
and delivery efficiency. 
 Successful delivery through this site also requires the drug to be in solution 
form before it arrives in the colon or alternatively, it should dissolve in the 
luminal fluids of the Colon, but this can be a limiting factor for poorly soluble 
drugs as the fluid content in the colon is much lower and it is more viscous 
than in the upper part of the GIT. 
 Lower surface area and Relative „tightness‟ of the tight junctions in the Colon 
can also restrict drug transport across the mucosa and into the systemic 
circulation 
1.5.3. FACTORS TO BE CONSIDERED IN THE DESIGN OF COLON-
SPECIFIC DRUG DELIVERY SYSTEM
5, 11
 
1.5.3.1. Anatomy and Physiology of Colon 
The GIT is divided into Stomach, Small Intestine and Large Intestine. The 
Large Intestine extending from the ileocaecal junction to the anus is divided into three 
main parts. These are the colon, the rectum and the anal canal. The colon itself is 
made up of the caecum, the ascending colon, the hepatic flexure, the transverse colon, 
the splenic flexure, the descending colon and the sigmoid colon. It is about 1.5 meters 
long. The transverse colon being the longest and most mobile part and has an average 
diameter of about 6.5 cm, although it varies in diameter from approximately 9 cm in 
caecum to 2 cm in the sigmoid colon. The Colon is a cylindrical tube that is lined by 
moist, soft pink lining called mucosa; the pathway is called the lumen and is 
approximately 2-3 inches in diameter. It includes caecum, colon and rectum. Caecum 
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forms the first part of the colon and leads to the right colon or the ascending colon 
followed by the transverse colon, the descending colon, the sigmoid colon, rectum 
and the anal canal. The major function of the colon is to create a suitable environment 
for the growth of colonic microorganisms, absorption of potassium and water from 
lumen concentrating the faecal content and secretion & excretion of potassium and 
bicarbonate, storage reservoir of faecal contents and expulsion of the contents of the 
colon at an appropriate time. 
 
Fig. No - 2: Anatomy of Colon 
Table No - 1: Transit time of different parts of GIT
5, 6, 11
 
Part of GIT Transit time 
Stomach < 1 hours (Fasting)  
> 3hours (Fed)  
Small intestine transit  
 Duodenum 
 Jejunum  
 Ileum  
 
5 minutes 
2 hours 
3 to 6 hours 
Large intestine transit 
 Caecum 
 Colon 
 
0.5 to 1 hours 
6 to 12 hours  
 
 
 
INTRODUCTION 
 
Department of Pharmaceutics, Madras Medical College Page 14 
 
1.3.5.2: pH in the various parts of GIT
5, 11
 
Table No – 2: pH in the different parts of GIT 
Location pH 
Oral cavity 6.2-7.4 
Oesophagus 5.0-6.0 
Stomach 
Fasted condition – 1.5 to 2.0 
Fed condition – 3.0 to 5.0 
Small intestine 
Jejunum – 5.0 to 6.5 
Ileum – 6.0 to 7.5 
Large intestine 
Right colon – 6.4 
Mid colon and Left colon – 6.0 to 7.6 
 
1.3.5.3: pH dependent system as an approach for Colon targeting
4
 
 The basic principle in this method is the coating of the dosage form with 
various pH-dependent polymers which protects the drug release in upper GIT and 
produces the delayed release products. The selected polymer for the Colon targeting 
should be able to withstand the pH in stomach and small intestine. Methacrylic acid 
esters are commonly used polymers for Colon targeting because they are soluble at 
pH above 6. The ideal polymer characteristic used in Colon targeting is to prevent the 
drug release in the stomach and the proximal part of small intestine, but able to 
dissolve in nearly neutral or alkaline pH of terminal ileum and ileocaecal region. 
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Fig. No – 3: Mechanism of drug release by pH-dependent system to Colon 
1.3.5.4. Delayed (Time-controlled release system) release Drug Delivery to Colon 
 Small Intestinal transit time is relatively constant and is hardly influenced by 
the nature of the formulation administered. The formulation once having left the 
stomach, the formulation arrives at the ileocaecal junction about 3 to 4 hours after 
dosing. The pH dependent polymers are utilized for this type of formulation. The drug 
release will occurs after a particular lag time.  
2. LITERATURE REVIEW 
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1. Murat Turkoglu et al., 
14
 developed pectin–HPMC Compression Coated 5-Amino 
Salicylic Acid Tablets for Colonic delivery. They Prepared 5-ASA Core Tablets by 
wet granulation method using PVP (K 29-32). Each 100 mg Core Tablet contained   
5-ASA and was compression coated at 20 kN or 30 kN using 100% pectin, 80% 
Pectin–20% HPMC and 60% pectin–40% HPMC at two different coat weights as 400 
or 500 mg. Drug dissolution/system erosion/degradation studies were carried out in     
pH - 1.2 and 6.8 buffers using a pectinolytic enzyme. HPMC addition was required to 
control the solubility of pectin. The optimum HPMC concentration was 20% and such 
system would protect the cores up to 6 h that corresponded to 25–35% erosion and 
after that under the influence of pectinase the system would degrade faster and 
delivering 5-ASA to the Colon.  
 
2. Toyohiro Sawada et al., 
15
 developed Time-release Compression Coated Core 
Tablet containing Nifedipine. The Solid dispersion of Nifedipine was prepared by 
spray drying method. The Core Tablets of Nifedipine were prepared by direct 
compression technique. The Compression coating is done by using different 
concentrations of polyethylene oxide-polyethylene glycol mixtures. Four formulations 
were done. Each formulation showed a clear lag period before Nifedipine release 
initiation, followed by sustained drug release lasting up to 24 h. The plasma 
Nifedipine profiles after oral administration of CC-2 Tablet suggest that a formulation 
that achieves clinically appropriate plasma Nifedipine concentration in the early 
morning might effectively regulate the morning surge in blood pressure responsible 
for myocardial infarction and stroke in hypertensive patients. 
 
3. Eiji Fukui et al., 
16
 formulated and evaluated the Timed-release Press Coated 
Tablets of Diltiazem hydrochloride (DIL) as a model drug for Colon targeting. Outer 
shell composed of Hydroxypropylcellulose. The Core Tablets were prepared by wet 
granulation method using 33% w/v PVP ethanolic solution as binder. In-vitro drug 
release study was done in JP 1
st
 fluid (pH-1.2) and JP 2
nd
 fluid (pH-6.8) indicated that 
these Tablets showed both acid resistance and Timed-release. ETP Tablets with a 
layer of phenylpropanolamine hydrochloride (PPA) (a marker of gastric emptying) 
between the enteric coating layer and outer shell were prepared and tested in beagle 
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dogs. The gastric emptying time and lag time after gastric emptying were evaluated 
by determining the times at which PPA and DIL first appeared in the plasma. 
 
4. Nikhil Biswas et al., 
17
 developed Pulse release of Doxazosin from 
Hydroxyethylcellulose Compression Coated Tablet. The Core Tablets were prepared 
by direct compression method. The influence of disintegrants CCS, l-
Hydroxypropylcellulose (l-HPC), gellan gum on drug release and in-vivo performance 
were investigated. The compression coating is done by using Ethyl cellulose and PEG 
6000. In-vitro optimized Croscarmellose sodium–HEC matrix showed significantly 
faster (p < 0.05) drug release (t90%= 46 min) after an initial lag of 243 min. 
Disintegrant –HEC blended matrices were found significantly superior    (p < 0.05) in 
terms of in-vitro release and bioavailability in comparison to plain HEC matrices. 
 
5. Sateesh Kumar Vemula et al., 
18
 formulated and evaluated Colon-specific double 
Compression Coated Mini-Tablets of Ketorolac tromethamine. Double Compression 
Coated Tablets were prepared based on Time-controlled Hydroxypropyl 
methylcellulose K100M inner compression coat and pH-sensitive Eudragit S-100 
outer compression coat. 6 formulations were done. From the in-vitro drug release 
studies, F6 Tablets was considered as the optimized formulation, which retarded the 
drug release in stomach and small intestine (3.51 + 0.15% in 5 h) and progressively 
released to colon (99.82 + 0.69% in 24 h). The release process followed supercase-II 
transport with zero order release kinetics. From the pharmacokinetic evaluation, the 
Immediate-release Core Mini-Tablets reached peak plasma concentration (C-max of 
4532.68 + 28.14 ng/ml) at 2 h T-max and Colon targeted Tablets showed C-max of 
3782.29 + 17.83 ng/ml at 12 h T-max. The area under the curve and mean resident 
time of Core Mini-Tablets were found to be 11,278.26 + 132.67 ng.h/ml and 3.68 h 
respectively while 17,324.48 + 56.32 ng.h/ml and 10.39 h for Compression Coated 
Tablets. 
 
6. SM Chick Petty et al., 
19
 developed novel Combined Time dependent Solvent less 
Compression Coated Delivery Systems for Colonic Delivery of Diclofenac Sodium. 
The present study was aimed to develop rapidly disintegrating Diclofenac sodium 
Core Tablets compression coated with a mixture of time dependent hydrophilic 
swellable polymer hydroxy propyl methyl cellulose (HPMC) and pH responsive 
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soluble polymer Eudragit S-100 in different ratios. The formulations released 1.24% 
to 6.82% of drug in physiological environment of stomach and small intestine 
depending upon proportion of HPMC and ED in the coat. The Core Tablets 
compression‐coated with HPMC and ED mixture in the ratio 6:4 was found to be 
suitable for targeting Diclofenac sodium to the Colon owing to its minimal drug 
release in physiological environment of stomach and small intestine and releases 92% 
of drug in the target area.  
 
7. Patel Rushikesh Chandubhai et al., 
20
 formulated and evaluated an oral Time- 
controlled Drug Delivery System of Flurbiprofen, based on chronotherapeutic 
approach for the treatment of Rheumatoid arthritis (RA). In this study, Flurbiprofen 
CCT were prepared by compression coating the Core Tablet with different polymers 
like HPMC K4M, HPMC K15M and HPC in various proportions. Different ratios of 
polymers were selected to achieve suitable lag time for the treatment of RA. The CCT 
were evaluated for their hardness, thickness, friability, weight variation, drug content 
uniformity and core erosion ratio. The in-vitro drug release profile of the formulations 
was performed in simulated gastric and intestinal pH conditions up to 8 h. The desired 
lag time of 6 h was obtained for selected formulations and burst release was obtained 
after the lag time, which was consistent with the demands of chronotherapeutic drug 
delivery.  
 
8. Dr. S.S. Khadabadi et al.,
 21
 formulated and evaluated the Press Coated Tablet of 
Ketoprofen. The PCT containing Ketoprofen in the inner core were formulated by 
direct compression method. SSG is used as a super disintegrant in Core Tablet. The 
HPMC K4M is used as a coating material to modify the release in outer coat. Totally 
9 formulations were made by varying amounts of SSG and HPMC K4M. Evaluations 
were done. The release profile of PCT exhibited a lag time depending upon the 
amount of HPMC K4M in compression coating, followed by burst release. 
Optimization was done using 32 factorial design considering two independent factors 
at three levels. The optimized batch F6 gave a lag time of 6 h and drug release of 
95.74% which consisted of 40% HPMC K4M and 2% SSG. 
 
9. Timucin Ugurlu et al., 
22
 developed the Compression Coated Nisin Tablets using 
Pectin/HPMC polymer mixture for Colonic delivery. In this study, each 100 mg Core 
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Tablet of Nisin was compression coated with 100% pectin, 90% pectin–10% HPMC, 
85% pectin–15% HPMC, 80% pectin–20% HPMC, 75% pectin–25% HPMC, 100% 
HPMC at a coat weight of 400 mg. Core Tablets of Nisin is formulated by wet 
granulation method. The concentration and the activity of Nisin were quantified using 
Well Diffusion Agar Assay. Drug release studies were carried out in pH-3.3 buffer 
solution. System degradation/erosion experiments were carried out in pH-1.2, 3.3, and 
6.8 buffers using a pectinolytic enzyme. It was found that pectin alone was not 
sufficient to protect the Nisin containing Core Tablets. At the end of the 6 h 40% 
degradation was observed for 100% pectin tablets. HPMC addition required to control 
the solubility of pectin, a 5% increase in HPMC ratio in pectin/HPMC mixture 
provided a 2 h lag time for Nisin release. 
 
10. Pruthviraj S Pawar et al., 
23
 formulated and evaluated the oral Colon targeted 
Compression Coated Tablet of budesonide. Colon targeted Tablets of budesonide 
were prepared using pectin, guar gum as enzyme dependent polymers along with 
HPMC, HEC as time dependent polymers followed by pH-dependent polymers like 
Eudragit S100 and Cellulose acetate phthalate. Fast dissolving core tablet of 
Budesonide was prepared by using CCS as a superdisintegrant by direct compression 
method which showed rapid release within 2 min. The compression coating was done 
over the Core Tablets by using pectin, guar gum, HPMC and HEC in different ratios 
by direct compression method. The enteric coating was done on the CCT using ED   
S-100 and CAP in different ratios by dip coating method. The evaluations were done 
for all the formulations. In-vitro swelling and in-vitro drug release studies were 
carried out at different pH (1.2, 6.8 and 7.4). The compression coated formulation C1 
(pectin: guar gum 1:2), C2 (HPMC: HEC 1:2) and C3 (HPMC, HEC: pectin, guar 
gum 2:1) showed good swelling (493.42%, 411.08% and 393.61%) up to 18, 20 and 
21 h respectively. pH dependent polymers ED S-100: CAP in the ratio 2:1 as an 
enteric coating material applied over CCT was capable of protecting the drug from 
being released in physiological environment of stomach and small intestine. This 
study proved that Budesonide CCT, enteric coated with ED S-100: CAP in the ratio 
2:1 may be beneficial in the treatment of IBS and Nocturnal Asthma. 
 
11. Ashwini Rajendra et al., 
24
 Designed and evaluated the compression coated 
formulations for an Antiinflammatory drug based on modified okra mucilage using 
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Diclofenac sodium as a model drug. In this present study fast disintegrating Core 
Tablets of Diclofenac sodium were coated with coating material granules containing 
okra mucilage or modified okra mucilage in combination with HPMC K15M (totally 
10 formulations are made) and evaluated for pre and post compression parameters. 
The in-vitro disintegration time for Core Tablets was 64.66±0.577 sec. and the 
wetting time was 41.66 ±0.57 sec. All other parameters were satisfactory for core and 
coated formulations. Formulations P1, P2 and P3 showed drug release of 96.789 ± 
0.66994%, 100.86 ± 0.42729% and 95.15±0.7180 % in 24 h respectively. There was 
no significant difference in in-vitro dissolution in presence and absence of rat caecal 
content indicating drug release depends on pH, swelling and erosion. 
 
12. Krishnaveni.G et al., 
25
 Developed and Evaluated of Pulsatile Drug Delivery 
System containing Montelukast Sodium by Press Coated Tablet using Natural 
Polysaccharides. Totally 9 different Montelukast sodium Core Tablet formulations 
were prepared by direct compression method using different concentrations of SSG, 
CCS, Crospovidone. Then the optimized F3 formulation was coated with a natural 
polymers such xanthan gum, guar gum and mixture of it respectively. The evaluations 
were done. Formulation P5-F3 shows great ideal in pulsatile drug delivery. The 
release data from the formulation was found to fit in peppas model with r
2
 of 0.983. 
Stability studies also performed for 3 months at 40ºC and 55ºC at 75% RH as per ICH 
guidelines for optimized formulation and it was found to be stable. 
 
13. Tarak J. Mehta et al.,
 26
 optimized Metronidazole Compression Coated Tablets. 
The Core Tablets were prepared by wet granulation method using PVP-K30 as binder. 
SSG is used as super disintegrant.  Chitosan and Carbopol 934-P is utilized to coat the 
Metronidazole Core Tablets in different concentrations. The evaluations were done 
for all the formulations. Optimization was performed using a 32 full factorial design. 
 
14. K. V. Krishna et al., 
27
 designed and evaluated the Extended-release Tablet of 
Venlafaxine hydrochloride using Compression coating technology. Venlafaxine HCl 
pellets were prepared. The compression coating of the pellets are done by both direct 
compression method and wet granulation method. As per USP Dissolution profiles for 
Compression Coated Tablets formulated by direct compression method and 
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Compression Coated Tablets formulated by wet granulation method are performed in 
0.1 N HCl. 
 
15. Nandini et al., 
28
 formulated and evaluated the Compression Coated Tablets Of 
Cefpodoxime Proxetil. The floating Core Tablets are prepared by direct compression 
technique. 9 formulations were made by using polymers such as HPMC, EC, Xanthan 
gum, Carbopol. Then Core Tablets were coated with coating material containing CCS 
in Immediate-release. This outer layer is so formulated to release its drug content in a 
period of 15 min, so as to achieve the initial burst release and then after 2 hours as the 
plasma concentration of the drug decreases then the core layer starts releasing its drug 
content so that the plasma concentration of the drug is maintained in the therapeutic 
window for the duration of 12 h. Thus the dosing interval is increased from 4 h to    
12 h. 
 
16. Sagar J. Sonawane et al.,
29
 developed and evaluated the Press Coated Tablets of 
Losartan potassium. The inner Core Tablets were prepared by direct compression 
method. SSG is used as Super disintegrant. The coat layer consists of HPMC K100M 
and Ethyl cellulose in different ratio. Results of in- vitro drug release profile from all 
formulations (F1-F4) showed slow and sustained release of Losartan potassium over a 
period of 12 hours. Hydrophilic polymers like HPMC K100M (60%) and Ethyl 
cellulose (10%) was found to be optimum. 
 
17. Yeswanth reddy musukula et al., 
30
 designed and evaluated the Compression 
Coated Colon Targeted Tablets of Ketorolac tromethamine by using Natural polymers 
and their combination with HPMC K100M. In this study, they develop Compression 
Coated Tablets of Ketorolac Tromethamine (KTM) with a view of minimizing the 
drug release in the physiological environment of stomach and small intestine and to 
achieve maximum drug release in the physiological environment of Colon by 
applying Natural polymers like Xanthan Gum, Guar Gum, Karaya Gum and 
combination of Xanthan Gum/ Guar Gum with HPMC K100M as a compression coat 
over the KTM Core Tablets. The KTM Core Tablets are prepared by direct 
compression method. The Compression coating is done by using polymers such as 
Xanthan gum, HPMC K100M, Guar gum, Karaya gum. The results of the study 
indicate that Tablets compression coated with Xanthan gum, combination of Xanthan 
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gum with HPMC K100M / Guar gum would be potential in delivering the drug to the 
Colon.  
 
18. D. Pavani et al., 
31
 developed and evaluated the Metoprolol Tartrate Compression 
Coated Tablets for Chronotherapeutic drug delivery system. The Core Tablets of 
Metoprolol Tartrate was prepared by direct compression method using various 
concentrations of super disintegrants. Three different formulations of Core Tablets 
were formulated. From this F1 shows faster drug release. Then the coating is done by 
using Ethyl cellulose N 50 and Methocel K100M. All the Core and Press Coated 
Tablet formulations were subjected to various physical and chemical evaluation tests 
for Core and Press Coated Tablets. Ten formulations of Compression Coated Tablets 
were made. From this C1, C2 and C3 produces maximum drug release after 3 hours, 
C5 and C9 produces maximum drug release after 8 hours. Time-dependent Pulsatile 
Drug Delivery System has been achieved from Tablet of formulation C5 and C9 with 
98.37% and 99.9%. 
 
19. Dahal Amit et al., 
32
 designed and evaluated the Compression Coated Tablets of 
Nifedipine. In this study, Core Tablets are prepared using solid dispersion of 
Nifedipine. Solid dispersion contains Nifedipine : Mannitol (1:2), prepared by hot 
melt method. The coat layer consists polymers such as PEG 6000, HPMC K4M, 
HPMC K15M and HPMC K100M in different ratios. Totally 12 formulations were 
done. All the evaluation parameters are checked out for both Core and Compression 
Coated Tablets. The mechanism of drug release was Higuchi’s model release kinetics 
with r
2 
value between 0.983-0.997. Hence, Compression Coated Tablets of Nifedipine 
prepared with hydrophilic polymers showed promising results to be chosen for 
chronotherapeutic treatment of Hypertension. 
 
20. Kommineni veditha et al., 
33
 designed and developed the Pulsin cap and Press 
Coated Tablets of Salbutamol sulphate. Press coated systems were prepared with 
different ratios of swelling and rupturable polymers [HPMC: Eudragit]. The lag time 
was dependent on composition of these polymers and the desired lag time was 
observed form the formulation containing only Eudragit. Modified Pulsin cap is based 
on cross linked hard gelatin capsules with formaldehyde and filled with Hydrogel 
plug. The Hydrogel plug plug was prepared with different ratios of swellable polymer 
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HPMC and diluent Dicalcium phosphate. The lag time was dependent on the polymer 
and diluent ratio. The desired lag time was observed form the formulation containing 
HPMC: DCP (3:1) ratio. Pulsin cap technique was found to be more suitable to 
achieve prolonged lag time when compared with the Compression Coated Tablets. 
 
21. Mohd abdul hadi et al., 
34
 formulated and evaluated of Compression Coated 
Tablets of Lornoxicam for targeting early morning peak symptoms of Rheumatoid 
Arthritis. The Core Tablets of Lornoxicam were prepared by direct compression 
technique using different concentration of Crospovidone. From this, the optimized 
formulation is compression coated with combination of different concentrations of 
polymers such as HPMC K4M, L-HPC, Na-CMC and EC (18-22 cps). Pre and post 
compression parameters were studied. The F5 formulation was chosen as better one as 
it releases 9.13 + 0.79% and 99.81 + 0.81% at the end of 5.5 and 8 hours respectively. 
 
22. J.Josephine leno jenita et al.,
 35
 formulated and evaluated the Compression 
Coated Tablets of Mesalazine for Colon delivery. In this study, Natural 
Polysaccharide; Locust bean gum (550,450,350 and 250 mg) are used. The in-vitro 
release studies carried out in 0.1 N HCl, Phosphate buffer pH-7.4 and Phosphate 
buffered saline pH-6.8 containing 4% w/v of rat caecal contents. These studies proved 
the Locust bean gum can able to protect the Core Tablet containing Mesalazine under 
conditions mimicking Mouth to Colon transit and clearly established that Locust bean 
gum in the form of compression coat is a potential carrier for Colon targeting.  
 
23. Renu dinkar et al.,
 36
 developed and evaluated the Nifedipine loaded Tablet 
formulation for Colonic delivery. The objective of present study was to develop a 
Pulsatile Compression Coated Tablet.  The Core Tablets of Nifedipine were prepared 
by wet granulation method.  Then the Core Tablets are coated with different ratios of 
Ethyl cellulose and Eudragit L-100. Six formulations were made by varying coating 
level (%w/w of core) and weight ratio of Ethyl cellulose to Eudragit L-100. The drug 
release study is carried out in 0.1 N HCl for 2 hours and in Phosphate buffer pH-6.8 
for 10 hours. The formulation having coating level of 50 % w/w of core and weight 
ratio of Ethyl cellulose to Eudragit L-100 (20%) produces the lesser release profile 
when compared to other formulations.  
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24. Sayantan mukhopadhyay et al., 
37
 formulated and evaluated the Pulsatile Drug 
Delivery System for sequential release of Atorvastatin. The Core Tablets of 
Atorvastatin were prepared by direct compression technique using SSG as super 
disintegrants. Then the Core Tablets are coated with the different concentrations of 
polymers such as Eudragit RS-100, Eudragit S-100, Ethyl cellulose, CAP, HPC. All 
prepared Multilayered Tablets were subjected for evaluation parameters. In-vitro drug 
release profiles of the prepared tablets were suggested that, the release of drug from 
Compression Coated Tablets match with chronobiological requirement of disease. 
 
25. M.R. Patel et al., 
38
 developed the Colon targeted Enteric Coated Matrix Tablet of 
Tegaserod maleate. The Matrix Tablets were prepared by direct compression 
technique. In this study, the enteric polymers such as Eudragit RLPO and Eudragit 
RSPO were utilized alone as well as mixture in different concentrations for Colon 
targeting. The formulated tablets were evaluated. The dissolution study is carried out 
in 700 ml of 0.1 N HCl was used as dissolution media for 2 hours followed by          
10 hours study at pH-6.8 by adding 200 ml of 0.2 mol/L Trisodium phosphate in 
dissolution media. 
 
26. Kamat Akshay Ramesh et al., 
39
 formulated and evaluated the Indomethacin 
Compression Coated Tablets using Natural polymers for Pulsatile Drug Delivery for 
the treatment of Rheumatoid Arthritis. The Immediate-release Core Tablets of 
Indomethacin is formulated by direct compression method. Plantago ovata mucilage 
and Modified agar is utilized in the Core Tablet formulation as super disintegrants. 
The external coat is formulated using the Natural polymers such as Dammar gum, 
Chitosan, Xanthan gum and Guar gum by both direct compression and wet 
granulation method. The formulated Tablets were evaluated for various pre and post 
compression parameters. Formulation prepared by wet granulation method containing 
Xantane gum and Dammar gum in the ratio of 2:1 having maximum lag time of 7 
hours 15  minutes. 
 
27. P.Shafi et al., 
40
 designed the Pulsatile Drug Delivery System of Lansoprazole by 
using Compression coating technology. The Lansoprazole Core Tablets are 
formulated by direct compression method. The coating was done by mixtures of 
Ethylcellulose (rupturable material) and Klucel EXF (erodible material) in different 
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concentrations and mixtures of Klucel HF (gellable material) and Klucel EXF 
(erodible material) in different concentrations. Then all the formulations are 
evaluated. 
 
28. Sateesh Kumar Vemula et al., 
41
 formulated and evaluated the Flurbiprofen 
CCT. Direct compression method was used to prepare flurbiprofen Core Tablets using 
CP as super disintegrants. Then the Core Tablets were compression coated with 
different concentrations of Guar gum. Then all the formulated Tablets were evaluated 
and optimized based on dissolution profiles. The optimized formulation provide the 
complete drug release in the Colon (99.86% ) within 24 hours, drug loss in the initial 
period of 5 hours is only about 6.84%. 
 
29. Halba PD et al., 
42
 formulated and evaluated the Enteric Coated Delayed-release 
Tablets of Omeprazole for Duodenal Ulcer. The Core Tablets were prepared by direct 
compression method using different concentration of CP as super disintegrant. Then 
the Core Tablets were subcoated with the HPMC 15 cps upto 3% weight gain 
followed by enteric coating with Eudragit L-100, Eudragit L 100-55 and Cellulose 
Acetate Pthalate. Pre and post compression evaluations were studied. In-vitro drug 
release studies were carried out in 0.1 N HCl and phosphate buffer pH-6.8.  
 
30. M. Bajpai et al.,
 43
 designed and evaluated the Compression Coated Tablets of 
Losartan Potassium. The purpose of the present work was to develop Pulsatile release 
Tablet of Losartan potassium for chronotherapy in Hypertension. The Core Tablets 
were prepared by direct compression method. Two types of Core Tablets were 
prepared, one containing CP as super disintegrant and other containing effervescent 
agent. Three types of granules were prepared by using three different polymers i.e. 
sodium carboxymethyl cellulose (Na-CMC), HPMC K4M, and HPMC E50 for 
coating of Core Tablets. Film coating is done over CCT to enhance the physical 
appearance. Then all the tablet formulations were evaluated.  
 
31. Janugade B. U et al.,
 44
 formulated and evaluated of Press Coated Montelukast 
sodium Tablets.  The Core Tablets of Montelukast sodium is prepared by direct 
compression method using CCS as super disintegrant. outer barrier layer consist of 
different concentrations of hydrophobic polymer Ethylcellulose and hydrophilic 
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polymer low-substituted Hydroxypropylcellulose. The outer barrier layer is prepared 
by both dry blending and wet granules for coating of Core Tablets. It was observed 
that lag time decreases with increasing concentration of low-substituted 
hydroxypropylcellulose. Press Coated Tablets coated by dry mixing and by wet 
granulation showed variations in lag time. As compared to dry mixed blend method 
wet granulation method gives less lag time. 
 
32. Haiqin Huang et al., 
45
 developed Compression Coated Tablets of Glipizide. The 
purpose of this study was to design a zero order release of CCT. The Inclusion 
complex of Glipizide was prepared using β-Cyclodextrin as carrier. Then the Core 
Tablets were prepared by using wet granulation method using HPC-L kneaded with 
ethanolic solution as binder. Wet granulation method was applied to prepare the 
partial granules of the compression coated layer. The formulated Tablets were 
evaluated. 
 
33. MD Wasimul Hasan et al., 
46
 formulated and evaluated the Press Coated Tablets 
of Salbutamol sulphate for Time-controlled release. The Core Tablets were prepared 
by direct compression. The Immediate-release Core formulations comprised of 
Salbutamol sulphate using super disintegrants such as Crospovidone, CCS and SSG in 
different ratios. The outer coat formulations were prepared using a hydrophilic 
(HPMC) and hydrophobic (EC) polymer of similar viscosity. The various evaluation 
parameters were studied. The formulation containing 300 mg of EC N-50 and         
75-100 mg of HPMC E-50 regarded as the minimum quantity required in outer press 
coat so as to attain a predetermined lag time of 6 h. 
 
34. Sateesh Kumar Vemula et al., 
47
 formulated and evaluated Colon-specific 
Double Compression Coated Tablets of Ketorolac tromethamine. The inner 
compression coat made of SSG as swelling layer and the outer compression coat 
made of Sodium alginate and Hydroxypropyl methylcellulose K15M. From the in- 
vitro drug release studies, F5 Tablets was considered as the optimized formulation, 
which retarded the drug release in Stomach and Small Intestine (5.06 + 0.16% in 5 h) 
and progressively released to Colon (99.78 + 0.64% in 24 h). The Immediate-release 
Core Mini-Tablets reached peak plasma concentration C-max of 4425.23 ng/ml at   2 
h T-max and Colon targeted double Compression Coated Tablets showed C-max of 
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3456.47 ng/ml at 10 h T-max. The area under the curve value of Core and Double 
Compression Coated Tablets were found to be 10128.53 and 17,467.62 ng.h/ml 
respectively and mean resident time was 4.21 hours and 10.34 hours respectively. 
 
35. Afrasim Moin et al., 
48
 formulated and evaluated the Compression Coated 
Tablets of Amoxicillin Trihydrate. The Core Tablets were compressed and coated 
with hydroxypropyl methylcellulose (HPMC) of different viscosities with spray-dried 
lactose (SDL) as a pore former. The final Two-pulse release Tablet was prepared with 
the remaining drug fraction (to be released as the first Immediate-release pulse) with a 
disintegrant, giving the final Tablet. The Tablets were evaluated. The results showed 
that the Core Tablet disintegrated within 30 to 40 sec. and drug content ranged from 
97.85 to 98.23%. In-vitro drug release showed prolongation of lag time as polymer 
viscosity increased. With 25% HPMC and 75% SDL, drug release was 97.5% by the 
end of 8
th
, 9
th
 &10
th
 h and viscosity was 100, 400 and 4000 cps respectively. 
 
36. Zeina D Salman et al.,
 49
 optimized Amitriptyline hydrochloride oral fast 
dissolving films and performed in-vitro and in-vivo evaluations and bioavailability 
studies. Ten formulations were prepared by solvent casting method. The 
concentrations of Hydroxypropyl methylcellulose and Maltodextrin were altered. 
Then the prepared films were evaluated for folding endurance, thickness, drug 
content, in-vitro/in-vivo disintegration time & drug release and tensile test. The 
optimized formulation F8 containing HPMC 15 cps and Maltodextrin in 1:1 ratio 
provides minimum in-vitro/ in-vivo disintegration time 16.8 and 13.2 sec. respectively 
and highest dissolution rate i.e. 89.77% of drug released in 2 minutes and satisfactory 
mechanical properties. Then the optimized formulation were further evaluated for 
bioavailability studies. 
 
37. V. S. Brindha et al., 
50
 designed and evaluated the Swellable Osmotic Drug 
Delivery System of Amitriptyline hydrochloride. The swellable Osmotic Drug 
Delivery Systems containing Amitriptyline Core Tablets were prepared by using 
polymers such as Hydroxypropyl methycellulose , Sodium carboxy methyl cellulose, 
methylcellulose and coated using Cellulose acetate (5% w/w) dissolved in 
Dichloromethane and Methanol mixture (4:1) containing PEG-400 as plasticizer in 
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the concentration of 15% w/w. Then drilling was done by using Microdrill to provide 
a drug delivery orifice. Then all the prepared Tablets were evaluated. 
 
38. R.Vijaya et al., 
51
 prepared and evaluated the Amitriptyline hydrochloride Films 
for Transdermal Drug Delivery. The Matrix-type Transdermal Film was prepared by 
solvent evaporation method using two different polymers Eudragit RL 100 & 
Hydroxypropyl methylcellulose (HPMC) in different ratios using solvents such as 
Ethyl alcohol and Dichloromethane. Dibutyl phthalate was utilised as a plasticizer. 
Then the formulated films were evaluated for physical properties such as thickness, 
percentage moisture absorption, percentage moisture loss, drug content, folding 
endurance and flatness. The in-vitro release studies were performed using USP 
dissolution apparatus. The optimized film was further evaluated for skin permeation, 
stability and skin irritation studies. 
 
39. Krishnaveni manubolu et al., 
52
 prepared and characterized the Amitriptyline 
Buccal Films. In this study by using Muco-adhesive polymers, the Amitriptyline 
hydrochloride Muco-adhesive Buccal Films were prepared. Buccal Muco-adhesive 
Films were prepared by Solvent casting method. 6 different formulations were made 
by using HPMC in different concentration along with glycerin as plasticizer and 
acetone as solvent. All the evaluation parameters were studied. The formulation F6  
provide  96.41 % at the end of 80 minutes.  
 
40. Mohsin A.A et al.,
 53
 formulated and evaluated the Mouth dissolving Tablets of 
Amitriptyline hydrochloride. The direct compression techniques were utilized in this 
formulation. Super disintegrants such as Sodium starch glycolate, Croscarmellose and 
Crospovidone were utilized in this study. The formulated Tablets were evaluated. The 
hardness of the Tablets ranges between 2.0 to 4.0 Kg/cm
2
. The percentage friability 
was less than one and passes the uniformity of weight, the Tablets were deviating 
from the average weight within the permissible limits of + 7.5 %. Drug content of 
prepared Tablets between 98.54% to 101.23%.  Tablets containing Crospovidone 
(DC9) provides the better disintegrating character. The drug release for this 
formulation was calculated as 99.83% in 7 minutes.  
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AIM OF THE PROJECT WORK  
 The main objective of the present study is to formulate Colon targeted 
Compressed Coated Tablets containing Immediate-release (IR) Core Tablets 
of Amitriptyline hydrochloride for Irritable bowel syndrome (IBS). 
 Amitriptyline hydrochloride Core Tablets were prepared by wet granulation 
technique using different super disintegrants such as Sodium starch glycolate, 
Croscarmellose sodium and Crospovidone. 
 Compression coating of Core Tablets were done by using direct compression 
technique using pH-dependent polymers such as Eudragit L-100 and    
Eudragit S-100. 
PLAN OF WORK  
The present study was designed and planned as follows:  
I. Collection of Literature / Survey of Literature. 
II. Compatibility studies; 
 Physical compatibility study – at initial (room temperature) and accelerated 
conditions (40º + 2º C and 75% + 5% RH). 
 Chemical compatibility study – Fourier Transform Infra-Red Spectroscopic 
(FT-IR) study (identification and compatibility of drug and excipients). 
III. Preparation of Standard curves for Amitriptyline hydrochloride in three different 
medium.  
IV. Pre-compression parameters of drug and formulations.  
V. Formulation development of Amitriptyline hydrochloride Core Tablets; 
 Preparation of Amitriptyline hydrochloride granules by wet granulation 
method  
 Preparation of Immediate-release Amitriptyline hydrochloride Core Tablets 
VI. Evaluation of formulated Amitriptyline hydrochloride Core Tablets and 
Optimisation was done using Disintegration time and Drug release. 
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VII. Compression coating of Optimised Amitriptyline hydrochloride Core Tablets by 
direct compression method using pH-dependent polymers such as Eudragit L-100 and 
Eudragit S-100 
VIII. Evaluation of formulated Compression Coated Tablets; 
 Diameter and Thickness 
 Uniformity of weight 
 Hardness 
 Friability 
 Drug content 
 Disintegration test  
 In-vitro drug release study  
 Stability study of optimised formulation as per ICH guidelines 
4. RATIONALE OF THE STUDY 
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RATIONALE OF THE STUDY 
The main objective of this project work is to formulate Colon targeted 
Compression Coated Tablets of Amitriptyline hydrochloride to improve the 
therapeutic efficacy by increasing drug level in Colon for the treatment of Irritable 
Bowel Syndrome (IBS) which affect the lower GIT especially in Colon. The 
Amitriptyline hydrochloride Core Tablets Compression Coated with the pH-
dependent enteric polymer is one of the techniques for Colon targeting. 
Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder 
characterized mainly by abdominal pain and altered bowel habits resulting in either 
diarrhoea or constipation, an increase in visceral hypersensitivity and visceral pain, in 
absence of the organic pathology.  
In time, many terms were used such as; Irritable Colon, Spastic Colon, 
Nervous Colon.  
The treatment objectives are;  
       1. Symptoms improvement (pain, discomfort, bloating, constipation, diarrhoea)  
       2. Ameliorate the global assessment of symptoms of IBS  
       3. Improve the quality of life  
 
4.1. RATIONALE FOR SELECTION OF DRUG  
Anti-depressants are widely used for the treatment of IBS, though the 
mechanism of action is not fully understood. They work both centrally and 
peripherally, which fits in with current concepts of central and peripheral sensitisation 
of visceral afferents in IBS. Amitriptyline hydrochloride should only be given to 
patients with severe IBS, particularly those with diarrhoea-predominant painful IBS. 
 
4.2. RATIONALE FOR SELECTION OF POLYMER 
            pH-dependent polymers Eudragit S-100 and Eudragit L-100 can be used for 
this formulation of Compression Coated Tablets of Amitriptyline hydrochloride. 
These polymers are insoluble at lower pH values and get solubilized as the pH 
increases. The polymer can protect a formulation in Stomach and to some extent in 
Small Intestine.  
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4.3. RATIONALE OF SELECTION OF DOSAGE FORM  
Compression coating with the pH-dependent enteric polymer is one of the 
technique for Colon targeting. Irritable Bowel Syndrome (IBS) affects the lower 
GIT especially the Colon. Amitriptyline hydrochloride is a drug of choice for severe 
Diarrhoea-predominant IBS. Amitriptyline hydrochloride Compression Coated 
Tablets were formulated using pH-dependent polymers. 
 
5. DISEASE PROFILE 
 
Department of Pharmaceutics, Madras Medical College  Page 33 
 
5.1. Irritable Bowel Syndrome (IBS) 
54 - 61 
Irritable Bowel Syndrome is a part of a family of functional gastrointestinal 
disorders (FGIDs) in which there is disturbance of gastrointestinal functions in the 
absence of any known pathology changes. It is a chronic relapsing disorder 
characterized by abdominal pain, distension and disturbed bowel habit. Diagnosis 
depends mainly on symptom evaluation and clinical criteria and on ruling out the 
presence of other organic causes. There is currently no specific diagnosis test for IBS.  
The symptoms of the IBS are cramping, abdominal pain, diarrhoea, 
constipation or a combination of both diarrhoea and constipation, mucus discharge 
along with stools, bloating, straining at defecation, urgency and feeling of incomplete 
evacuation. It is chronic nature, signs and symptoms which vary periodically from 
mild to severe have many negative effects on the quality of life for the sufferer. 
Therefore the appropriate treatment of these patients is highly important.  
Depending on the predominant bowel symptoms, IBS can be classified as  
 Constipation predominant IBS (IBS-C) 
 Diarrhoea predominant IBS (IBS-D)   
 IBS with mixed constipation and diarrhoea (IBS-M) 
IBS is also known as Irritable Colon, Spastic Colon, Nervous Colon. 
 
Fig. No - 4: Colon in IBS 
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5.2. Etiology of IBS 
54, 55, 59 
The exact Etiology of IBS remains to be determined. The debate remains 
whether it is caused by hereditary or environmental factors. It is possibly due to 
complex interaction between both. A number of mechanisms have been described in 
the etiology of IBS as summarized below, 
 Visceral Hypersensitivity  
It is an important mechanism for abdominal pain in IBS. It is caused by 
heightened sensitivity of both peripheral and CNS due to inflammatory and 
non-inflammatory agents. 
 Abnormal Gut Motility  
A cardinal feature of IBS is change in bowel pattern which is due to 
abnormality of gut motility. Sympathetic and parasympathetic nerves control 
the function of enteric nervous system via. a variety of mediators and 
receptors such as serotonin. Activation of 5-HT3 and 5-HT4 receptors 
enhances gut motility while inhibition of 5-HT3 delays transit time. Gut 
motility is also regulated by psychogenic, somatic and immune stress.  
 Autonomic Nervous System Dysfunction  
There appears to be an imbalance resulting from increased sympathetic 
and decreased parasympathetic activity. Vagal and adrenergic dysfunctions are 
associated mainly with constipation and diarrhoea respectively.  
 Small Intestine Bacterial Overgrowth  
Up to 84% patients with IBS have been found to have Small Intestinal 
Bacterial Overgrowth (SIBO). Antibiotic treatment with non-absorbable 
antibiotics, e.g. Rifaximin leads to clinical improvement of IBS. Two studies 
suggest the prevalence of SIBO to be 11% in India. However, villous atrophy 
with bacterial overgrowth (tropical enteropathy) is also common in India. It is 
presently unclear whether SIBO is the cause or effect of IBS.  
 Microscopic Inflammation  
Microscopic inflammation has been documented in some patients. This 
concept is important because IBS has previously been considered to have no 
demonstrable pathologic alterations. Immuno histochemical studies reveal 
mucosal immune system activation in a subset of patients with IBS-D.  
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 Post-infectious Irritable Bowel Syndrome 
Post-infectious IBS affects 10% of IBS patients. This subtype is 
consequent to previous bacterial gastroenteritis and raises the importance of 
bacterial infections in causation of IBS. A longer duration of the diarrhoeal 
episode, younger age, female sex, bloody stools, depression, etc., increases the 
risk of development of IBS. Interestingly, some studies in India suggest a 
protective effect of previous exposure to amebic infection.  
 Food Intolerance and Allergy  
Hypersensitivity reactions lead to mast cell degranulation with 
production of local and systemic proinflammatory Leukotrienes and Histamine 
which act on smooth muscles. Sugar and Gluten intolerance have also been 
implicated but seem to be unlikely cause of IBS although may contribute to 
bloating.  
 Psychosocial Factors  
Emotions affect gut motility and patients with history of physical or 
sexual abuse, loss and separation during childhood, and conflicting maternal 
relationship are all associated with development of IBS. 
 Genetic Factors  
There is some evidence to suggest a genetic factor in causation of IBS. 
One study found that 33% of patients with IBS had a positive family history. 
Also, first-degree relatives are twice likely to have IBS. 
5.3. PATHOPHYSIOLOGY
 54, 55, 56
 
 The pathophysiology of IBS is poorly understood. Till now there is no single 
clear pathophysiology has been demonstrated. Theories includes;  
 Altered bowel motility  
Instead of the normal muscular activity (motility) of digestion, IBS 
patients may experience spasms and cramping. If the motility is too fast, it 
may result in diarrhoea and if it is too slow, it might result in constipation. 
These two conditions may also produce abdominal discomfort or pain in IBS 
patients. Abnormal motility can also be associated with abdominal cramping, 
belching, urgency or other unpleasant GI symptoms.  
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 Visceral Hypersensitivity  
For IBS patients, there can also be increased sensitivity of the nerves in 
the GIT. This can develop after a gastrointestinal infection or an operation that 
causes injury to the nerves in the intestine. This result in a lower threshold for 
experiencing intestinal sensations, leading to abdominal discomfort or pain. In 
those with visceral hypersensitivity, the stretch put on the intestines from 
eating even small amounts of food may produce discomfort.  
 Imbalance of neurotransmitters  
Serotonin is synthesized and released by Enterochromaffin cells in the 
GIT and plays an important role in regulation of GI-motility, sensation and 
secretion. Excess released serotonin is mopped up by the serotonin reuptake 
transporter (SERT). Several studies have indicated a noted imbalance in the 
functioning of 5-HT due to an impairment in its release and reuptake 
mechanisms by SERT in functional GI disorders which has in particular been 
shown be true IBS. 
  
Upto to 60 % of patients with IBS have psychiatric co-morbidities 
including depression, anxiety, somatization and functional disorders such as 
chronic fatigue syndrome.  
5.4. RISK FACTORS 
58
 
1. Gender and Age  
Younger age was found to be an independent risk factor for IBS 
development. IBS usually begins during the late teens or early 20’s. According 
to the American College of Gasteroenterology more than 80% of the IBS 
patients are women.  
2. Stress  
Stress induced release of Corticotrophin - Releasing Factor (CRF) may 
be responsible for mast cell activation and mediator release. It will leads to 
CRF infusion in IBS patients evokes an exaggerated colonic motor response.  
3. Food Allergy  
The symptoms of IBS are often made worse by eating, and this leads 
many patients to conclude that they are suffering from some form of dietary 
allerg. There is little evidence to suggest that immediate type IgE mediated 
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reactions are particularly important in IBS as a whole, although in those who 
suffer from diarrhoea.  
4. Smoking  
A single study showed smoking to be associated with Postinfective-
IBS (PI-IBS) development. However, smoking can be a marker for 
psychological distress, hence associating with PI-IBS, which makes it harder 
to draw any conclusions based on the limited evidence.  
5.5. SYMPTOMS 
54, 60 
Symptoms associated with IBS are; 
 Chronic abdominal pain  
 Altered bowel habits  
 Painful Diarrhoea and Painful Constipation 
 Mucus discharge along with stools 
 Straining at defecation 
 Feeling of incomplete evacuation 
 Upper GI symptoms include gastro-esophageal reflux, dysphagia, early 
satiety, intermittent dyspepsia, nausea and non-cardiac chest pain are 
noted as being common 
 Patient may also frequently complain of abdominal bloating and an 
increase in gas production in the form of flatulence or belching 
 Extra-intestinal symptoms include impaired sexual function, 
dysmenorrhea, dyspareunia, increase in the frequency and urgency to 
urinate, hypertension and asthma, fibromyalgia 
5.6. MANAGEMENT OF IBS 
54, 55, 56, 59
 
The IBS management is done in following steps;  
1. Dietary interventions  
2. Pharmacological therapy 
 Anti-spasmodic agents 
 Peppermint oil  
 Anti-diarrhoeal agents  
 Tricyclic antidepressants  
 Selective serotonin reuptake inhibitors (5-HT3 Antagonist) 
 5-HT4 Agonist 
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3. Probiotics 
4. Biopsychosocial modifying therapies:  
 Hypnotherapy 
 Cognitive behavioral therapy  
 Yoga 
 Acupuncture 
Dietary interventions  
Dietary interventions form an important strategy in managing children with 
IBS. Constipation is a common complaint in patients with IBS. The commonest 
dietary recommendation made to patients with IBS is to increase the intake of dietary 
fibre. Fruit and vegetable contain substantial amounts of both soluble (pectins, 
hemicelluloses) and insoluble (cellulose, lignin) fibre. Fibre supplementation with 
naturally derived concentrated non starch polysaccharides such as bran, ispaghula 
husk, methylcellulose and sterculia increases faecal mass and may accelerate transit.  
Anti-spasmodic agents  
Anti-spasmodics are believed to inhibit contractile pathways in visceral 
muscle walls and thus reduce abdominal pain. Anti-spasmodics can be classified in 
three major subclasses  
1. Anti-cholinergic / Anti-muscarinic agents  
 Dicyclomine Hydrochloride  
 Hyoscyamine Sulfate  
 Cimetropium Bromide  
 Otilanium Bromide  
 Octylonium Bromide  
 Prifinium Bromide  
 Zamifenacin  
 Darifenacin  
2. Smooth muscle relaxants  
 Mebeverine  
 Papaverine-like agents 
3. Calcium channel blockers  
 Pinaverium Bromide  
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Peppermint oil: 
 It exerts an Anti-spasmodic action via. menthol and act as a calcium 
antagonist and results in Anti-flatulent action, the exact mechanism of which currently 
remains unexplained.  
Anti-diarrhoeal agents 
It is useful for the treatment of IBS-D but has little effect on abdominal pain. 
The opioid analogues stimulate inhibitory presynaptic receptors in the enteric nervous 
system resulting in inhibition of peristalsis and secretion. e.g. Loperamide and 
Diphenoxylate.  It has a better safety profile, since it does not cross the blood brain 
barrier like other opiates.  
Tricyclic Anti-depressants (TCAs)  
The tricyclic anti-depressants are drugs with anticholinergic and non-selective 
serotonin reuptake inhibitor effects. Anti-depressants are effective in treating 
symptoms of IBS and other functional GI disorders. They work both centrally and 
peripheral sensitization of visceral afferents in IBS. Patients who have taken Anti-
depressants for their IBS symptoms have reported significant improvement in their 
abdominal pain and reduction in other IBS symptoms such as diarrhoea, constipation, 
bloating, nausea. Tricyclic Anti-depressants are effective in the treatment of IBS 
patients at low doses. They are particularly used to treat severe IBS-D (not those with 
constipation, since this is a side effect of Anti-depressants). 
TCAs include;  
 Amitriptyline  
 Imipramine  
 Desipramine  
 Nortriptyline  
Amitriptyline  
 Amitriptyline, a Tricyclic Anti-depressant has been found to be effective in 
adults with IBS in producing global improvement, increasing feelings of wellbeing, 
reducing abdominal pain and increasing satisfaction with bowel movements. The 
beneficial effects of Anti-depressants can be explained by partial increments in the 
central pain threshold. 
Selective Serotonin Reuptake Inhibitors (SSRIs)  
Selective Serotonin Reuptake Inhibitors (SSRIs) are widely prescribed and 
well tolerated in the treatment of anxiety, depression and somatization disorders. 
DISEASE PROFILE 
 
Department of Pharmaceutics, Madras Medical College Page 40 
 
SSRIs (paroxetine) accelerated intestinal transit time - thus suggesting that SSRIs 
would be more suited for treating IBS-C.  
SSRI’s include;  
 Citalopram  
 Escitalopram  
 Sertraline  
 Paroxetine  
 Fluoxetine  
5-HT4 Agonist 
 Tegaserod is the peripheral 5-HT4 receptor agonist that binds to mucosal 5-
HT4 receptors and promotes gastric emptying and facilitates small and large bowel 
transit. Tegaserod (6 mg BD) is being used for the treatment of patients with 
constipation-predominant IBS. It also reduces sensitivity as well as severity of pain 
and bloating in such patients. However, its bioavailability is only 10 % and food 
further reduces its bioavailability. 
Probiotics  
Probiotics are a more attractive though possibly less effective way of altering  
bowel flora and five randomized placebo controlled trails of probiotics have shown 
benefit for some symptoms, notably bloating and flatulence using a variety of 
probiotic agents including Lactobacillus rhamnosus plantarum, VSL # 3 (a probiotic 
containing 8 beneficial species of bacteria) and a mixture of lactobacilli, 
bifidobacteria and a streptococcus.  
Hypnotherapy 
Hypnotherapy normalizes visceral sensation, reduces colonic phasic 
contractions and reverses the patients’ negative thoughts about their condition. 
Hypnotherapy activates certain areas of the brain, especially the anterior cingulate 
cortex, in response to a painful rectal stimulus appears to be exaggerated in IBS 
compared with controls. It is not suitable for the severe cases of IBS.  
Cognitive Behavioral Therapy (CBT)  
 CBT is also based on the assumption that IBS symptoms are a response to 
stressful life events or daily hassles, producing maladaptive behaviours and 
inappropriate symptom attribution. Treatment involves identifying the triggers for 
symptoms exacerbation, understanding the patients response to symptoms and 
teaching more adaptive ways of responding.  
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Yoga 
 Yoga can be considered as a form of behavioural therapy and consist of 
general relaxation exercises, breathing exercises, focused training for abdominal 
relaxation and positive reinforcement by focusing thoughts on a single topic and good 
experiences. 
Acupuncture 
 This is considered to relieve pain by release of endogenous opiates and 
triggering of serotoninergic inhibitory pathways. A study compared differences in the 
therapeutic effect of Tianshu acupuncture, Dachangshu acupuncture and western 
medication with Trimebutine maleate. Acupuncture was found to relieve symptoms of 
IBS.    
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AMITRIPTYLINE HYDROCHLORIDE 
63 - 67 
PHYSICOCHEMICAL PROFILE 
Chemical structure 
                                                      
Chemical Name          3-(10,11-dihydro-5H-dibenzo(a,d)cyclohept-5-ylidene)propyl 
 dimehtylamine  hydrochloride 
CAS Number             549-18-8 
Molecular Formula   C20H23N.HCl 
Molecular weight      313.9 
Category                   Anti-Depressant 
Description               Colourless crystals or a white or almost white powder,  
Almost odourless  
Solubility                  Freely soluble in water. 
Melting point           196 to 197ºC 
pH                             4.5 – 6.0, determined in a 1.0% w/v solution 
Loss on drying         Not more than 0.5 %, determined on 1.0 g by drying in oven         
at 105°C 
Sulphated ash          Not more than 0.1 % 
Storage                     Store at room temperature and in tightly closed container. 
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PHARMACOKINETIC PROFILE 
Absorption   : The oral absorption of Amitriptyline hydrochloride is good, 
though often slow. The Amitriptyline hydrochloride is well                  
absorbed in the gastrointestinal tract. 
Distribution : The Amitriptyline hydrochloride bind extensively to plasma  
proteins and have large volumes of distribution (Approximately   
20L/kg). Their half-lives ranges from 16–26 hours.  
Metabolism : Amitriptyline hydrochloride is extensively metabolized in 
Liver. The major route is Demethylation whereby active 
metabolite Nortriptyline is   formed. Tertiary amines are 
converted to secondary amines, which generally possess 
biological activity and are frequently in serum at levels equal to 
or greater than that of the parent tertiary amine. Various CYP 
isoenzymes like CYP 2D6, CYP 3A4, CYP 1A2 and others 
metabolise Tricylic Antidepressants. Drug inactivation 
generally occurs through oxidative metabolism by hepatic 
microsomal enzymes and Glucuronic acid conjugation.  
Excretion     : Metabolite is excreted in urine over 1-2 weeks. 
 
PHARMACOLOGICAL PROFILE  
Mechanism of action 
The mechanism of action of Amitriptyline hydrochloride is not fully 
understood. Amitriptyline hydrochloride has been found to be effective in adults with 
IBS in producing global improvement, increasing feelings of well-being, reducing 
abdominal pain and increasing satisfaction with bowel movements. The beneficial 
effects of Amitriptyline hydrochloride can be explained by partial increments in the 
central pain threshold. Other mechanisms by which Amitriptyline hydrochloride 
might exert the effects include Anti-cholinergic effects (may result improvement of 
diarrhoea), regulation of GI-transit and peripheral Anti-neuropathic effects. The Anti-
depressant activity is due to blocking the reuptake of Nor-epinephrine and Serotonin 
into their respective neuron by inhibiting their respective transporters. 
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Indication and usage 
 It is primarily used for the treatment of Depression 
 Amitriptyline hydrochloride also used for the treatment of; 
 Irritable Bowel Syndrome (IBS) 
 Attention Deficit Hyperkinetic Disorder(ADHD), 
 Neuropathic pains (reduces intensity in Post-herpetic neuralgia) 
 Migraine 
 Pruritus 
Dose 
10–25 mg once daily for IBS. 
Side effects 
Side effects of Amitriptyline Hydrochloride are Anticholinergic effects such 
as dry mouth, constipation, epigastric distress, sedation, cardiac arrhythmias, 
Precautions 
Caution is needed with history of seizures, urinary retention, urethral or 
ureteral spasm, angle-closure glaucoma or increased IOP, cardiovascular disorders, 
hyperthyroidism and patients receiving thyroid medication, hepatic or renal 
impairment, schizophrenia, paranoia. Serotonin syndrome: Some TCAs inhibit 
neuronal reuptake of serotonin and can increase synaptic serotonin levels. 
Interactions 
TCAs potentiate directly acting sympathomimetics (causing raise in BP and 
arrhythmias) but inhibit the effects of indirectly acting Sympathomimetics (block their 
uptake). Anti-cholinergic drugs aggrevate the toxicity of TCAs. Phenytoin, 
Chlorpromazine and  aspirin displace TCAs from protein binding site leads to 
toxicity. MAO inhibitors with TCAs show synergistic actions leading to serious 
toxicities (Hypertension, Arrythmiasis and Seizures). 
Brand names 
 Amitone (10,25,75 mg Tablet)  
 Tryptomer (10,25,75 mg Tablet) 
 Tadamit (10,25,75 mg Tablet) 
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PHARMACEUTICAL EXCIPIENTS 
62, 68 - 70 
Excipients are substances other than the pharmacologically active drug or 
prodrugs, which are included in the manufacturing process or contained in the 
pharmaceutical finished product or dosage form. 
Excipients play a wide variety of functional role in pharmaceuticals dosage forms 
including; 
 Modifies the solubility and bioavailability of active pharmaceutical ingredients 
(APIs). 
 Increasing the stability of active ingredients the dosage forms. 
 Maintaining the pH and/or osmolarity of liquid formulations. 
 Helping active ingredients maintained preferred polymorphic Forms or 
conformation 
 Modulating immunogenic responses of active ingredients (e.g. Adjuvants). 
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7.1. CROSCARMELLOSE SODIUM 
70 
Non-proprietary Name  
BP: Croscarmellose sodium, PhEur: Carmellosum natricum conexum, 
USPNF: Croscarmellose sodium  
Synonyms 
Ac-Di-Sol; croslinked carboxy methyl cellulose sodium; Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol  
Chemical Name  
Cellulose, carboxymethyl ether, sodium salt,cross-linked  
Empirical formula and Molecular Weight  
C12H10Ca3O14. 4H2O;         M.W: 570.49  
Functional Category  
Tablet and Capsule disintegrant  
Description:  
Croscarmellose sodium occurs as an odourless, white or grayish-white 
powder.  
Incompatibilities  
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly 
reduced in Tablet formulations prepared by either the wet-granulation or direct-
compression process that contain hygroscopic excipients such as sorbitol.  
Applications  
CCS is used as an Disintegrant in Capsule, Tablets and Granules. 
Croscarmellose sodium may be used in both direct compression and wet granulation 
processes. When used in wet granulation’s, the croscarmellose sodium should be 
added in both wet and dry stages of the process (intra and extra granularly) so that the 
wicking and swelling ability of the disintegrant is best utilized. Croscarmellose 
sodium at concentrations up to 5% w/w may be used as tablet disintegrant, although 
normally 2% w/w is used in tablets prepared by direct compression and 3% w/w in 
tablets prepared by wet granulation process. 
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7.2. SODIUM STARCH GLYCOLATE 
70
 
Non-proprietary Name  
BP: Sodium Starch Glycolate, PhEur: Carboxymethylamylum natricum , 
USPNF: Sodium Starch Glycolate  
Synonyms 
Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; 
starch carboxy methyl ether, sodium salt; Tablo; Vivastar P  
Chemical Name  
Sodium Carboxy Methyl Starch  
Functional Category  
Tablet and Capsule disintegrant  
Description  
Sodium Starch Glycolate is a white to off-white, odorless, tasteless, free-
flowing powder.  
Solubility  
Practically insoluble in methylene chloride. It gives a translucent suspension 
in water.  
Applications 
It is widely used in oral pharmaceuticals as a disintegrant in Capsule and 
Tablet formulations. It is commonly used in Tablet prepared by direct compression or 
wet granulation process. The usual concentration employed in formulation is between 
2% and 8%, with the optimum concentration of about 4%. Disintegration occurs by 
rapid uptake of water and enormous swelling. Increasing the tablet compression 
pressure also appears to have no effect on disintegration time. Sodium Starch 
Glycolate has also been investigated for use as a suspending vehicle. 
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7.3. CROS POVIDONE 
70
 
Non-proprietary Name 
BP: Crospovidone, PhEur: Crospovidonum, USPNF: Crospovidone  
Synonyms 
Cross-linked povidone; E1202; Kollidon CL; Kollidon CL-M; Polyplasdone 
XL; Polyplasdone XL-10; Polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-pyrrolidinone 
homopolymer  
Chemical Name  
1-Ethenyl-2-pyrrolidinone homopolymer  
Empirical formula and Molecular Weight  
(C6H9NO)n;                       M.W:   > 10,00,000  
Functional Category 
Tablet disintegrant  
Description 
Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odourless or nearly odourless, hygroscopic powder.  
Incompatibilities  
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adducts with some materials  
Applications 
Crospovidone is a water-insoluble tablet disintegrant used at 2-5% 
concentration in Tablets prepared by direct compression or wet and dry granulation 
methods. It rapidly exhibits high capillary activity and pronounced hydration capacity, 
with little tendency to form gels. Crospovidone can also be used as a solubility 
enhancer. With the technique of co-evaporation, crospovidone can be used to enhance 
the solubility of poorly soluble drugs. 
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7.4. GELATIN 
70
 
Nonproprietary Names 
BP: Gelatin  
JP: Gelatin 
PhEur: Gelatina 
USPNF: Gelatin 
Synonyms 
Byco, Cryogel, gelatin, Instagel, Solugel. 
Chemical Name 
Gelatin 
Empirical Formula and Molecular Weight 
Gelatin is a generic term for a mixture of purified protein fractions obtained 
either by partial acid hydrolysis (Type A Gelatin) or by partial alkaline hydrolysis 
(Type B Gelatin) of animal collagen. Gelatin may also be a mixture of both types. The 
protein fractions consist almost entirely of amino acids joined together by amide 
linkages to form linear polymers, varying in molecular weight from 15,000–25,0000. 
Description 
Gelatin occurs as a light-amber to faintly yellow-colored, vitreous, brittle 
solid. It is practically odourless and tasteless and is available as translucent sheets and 
granules or as a powder. 
Solubility 
 It is soluble in water at above 40ºC, forming a colloidal solution which gels on 
cooling to 35ºC to 40ºC. Practically insoluble in Acetone, Chloroform, Ethanol 
(95%), Ether and Methanol.  
Functional Category 
Coating agent, Film-former, Gelling agent, Suspending agent, Tablet binder, 
Viscosity-builder. 
Applications 
Gelatin is widely used in manufacturing of Capsules. In addition, it is also 
used as a Tablet binder and coating agent and as a viscosity-increasing agent in 
solutions and semisolids. Gelatin is also widely used in food products and 
photographic emulsions. 
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7.5. MAGNESIUM STEARATE 
70
 
Non-proprietary Name 
BP: Magnesium Stearate, JP: Magnesium Stearate, PhEur: Magnesii stearas, 
USPNF: Magnesium stearate 
Synonyms 
Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt.  
Chemical Name  
Octadecanoic acid Magnesium salt  
Empirical Formula and Molecular weight 
C36H70MgO4;     M.W: 591.24  
Functional Category 
Tablet and Capsule Lubricant  
Description  
Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odour of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
Incompatibility  
Incompatible with strong acids, alkalis and iron salts  
Applications 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a Lubricant in Capsule and Tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
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7.6. TALC 
70
 
Non-proprietary Name  
BP: Purified Talc, JP: Talc, PhEur: Talcum, USP: Talc  
Synonyms 
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore.  
Chemical Name  
Talc  
Empirical Formula & Molecular weight  
Mg6 (Si2O5)4(OH)4;        M.W: 379.27. 
Functional Category  
Anticaking agent, Glidant, Tablet and Capsule Diluents, Tablet and Capsule 
Lubricant.  
Description 
Talc is a very fine, white to grayish-white, odourless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness.  
Solubility  
Practically insoluble in dilute acids and alkalies, organic solvents and water  
Incompatibility 
Incompatible with quaternary ammonium compounds  
Applications 
Talc was once widely used in oral solid dosage formulations as Lubricant and 
Diluent. It is widely used as a dissolution retardant in the development of controlled 
release products. In topical preparations, Talc is used as a dusting powder, although it 
should not be used to dust surgical gloves Talc is additionally used to clarify liquids 
and is also used in cosmetics and food products, mainly for its lubricant properties. 
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7.7. LACTOSE 
70
 
Nonproprietary names 
BP: Lactose monohydrate, PhEur: Lactosum monohydricum, JP: Lactose, 
USPNF: Lactose monohydrate 
Synonyms  
CapsuLac, GranuLac, Lactochem, Lactosum monohydricum, Monohydrate.  
Empirical formula and Molecular weight  
C12H22O11H2O;                M.W: 360.31  
Chemical name  
O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose monohydrate  
Functional category  
Tablet binder, Tablet and Capsule diluent, diluent for dry-powder inhalers. 
Description  
Lactose occurs as white to off-white crystalline particle or powder. Lactose is 
odourless and slightly sweet-tasting. alpha-lactose is approximately 20% as sweet as 
sucrose, while beta-lactose is 40% as sweet. 
Solubility  
Freely but slowly soluble in water, practically insoluble in alcohol.  
Incompatibilities  
A Maillard type condensation reaction is likely to occur between Lactose and 
compounds with a primary amino group to form brown or yellow-brown coloured 
products. Lactose is also incompatible with Amino acids, Amphetamine, 
Aminophylline and Lisinopril.  
Application in Pharmaceutical Formulations  
Lactose is widely used as a filler or diluent in Tablets and Capsules and to a 
more limited extent in lyophilized products and infant formulas. Lactose is also used 
as a diluent in dry-powder inhalation. Lactose is also used in combination with 
sucrose (approximately 1 : 3) to prepare sugar-coating solutions. 
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7.8. EUDRAGIT L-100 
70
 
Nonproprietary Names 
BP: Methacrylic acid - Methyl methacrylate copolymer (1:1).  
PhEur: Methacrylic acid - Methyl methacrylate copolymer (1:1). 
USP-NF: Methacrylic acid copolymer. 
Synonym 
Polymeric methacrylates  
Chemical Name 
Poly(methacrylic acid, methyl methacrylate) 1:1  
Empirical Formula & Molecular Weight  
 (C18H28O8)n;                 M.W: Mean relative Molecular mass of about 1,35,000. 
Description 
White free - flowing powders with at least 95% of dry Polymers. 
Solubility 
Readily soluble soluble in neutral to weakly alkaline conditions (pH 6-7)  
Functional Category 
Film former; Tablet binder; Tablet diluent.  
Applications 
It is used as Enteric coating agents because they are resistant to gastric fluid.  
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7.9. EUDRAGIT S-100 
70
 
Nonproprietary Names 
BP: Methacrylic acid - Methyl methacrylate copolymer 1:2.  
PhEur: Methacrylic acid - Methyl methacrylate copolymer 1:2.  
USP/NF: Methacrylic acid copolymer  
Synonyms 
Polymeric methacrylates  
Chemical Name 
Poly(methacrylic acid, Methyl methacrylate) 1:2.  
Empirical Formula & Molecular Weight 
 (C18H28O8)n;                 M.W: Mean relative Molecular mass of about 135000. 
Description 
White free- flowing powders with at least 95% of dry Polymers. 
Solubility 
Readily soluble soluble in neutral to weakly alkaline conditions (pH 6-7)  
Functional Category 
Film former; Tablet binder; Tablet diluent.  
Applications 
It is used as Enteric coating agents because they are resistant to gastric fluid.  
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7.10. BRILLIANT BLUE FCF 
68 - 70
 
Nonproprietary Names 
FD&C blue #1, Brilliant blue FCF 
Synonym 
FD&C Blue No.1, CI Food Blue 2. 
Chemical Name 
Disodium 3- [N – ethyl – N -[ 4 - [ [ 4 - [ N- ethyl- N- ( 3 - sulfonatobenzyl) – 
amino ] phenyl ] ( 2 - sulfonatophenyl ) methylene ] - 2 , 5 - cyclohexa - diene - 1 
ylidene ] ammoniomethyl ] - benzenesulfonate; 
 Disodium I-[4-(N-ethyl-3-sulfonatobenzylamino)phenyl]-I- [4-(N-ethyl-3- 
sulfonatobenzyliminio)cyclohexa-2,5-dienyli-dene]toluene-2-sulfonate (an alternative 
chemical name). 
Formula and Molecular weight 
C37H34N2Na2O9S3;                  M.W: 792.85 
Description 
 Reddish-Blue powder or granules. 
Solubility 
Solubility of Brilliant blue FCF at 25°C:18 g in 100 ml of water, 1.5 g in 100 
ml of ethanol(95%), 20 g in ethanol(50%), 20 g in 100ml of glycerin. 
Functional category 
Colourant 
Applications 
Coloring agents are used mainly to impart a distinctive appearance to a 
pharmaceutical dosage form. The main categories of dosage form that are colored are;  
i. Tablets: either the core itself or the coating.  
ii. Hard or soft gelatin capsules: the capsule shell or coated beads. 
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Table No - 3: List of Materials and their application in formulation 
S.No. Name of the material 
Manufacturer / 
Supplier 
Use in 
formulation 
1 
Amitriptyline 
hydrochloride 
Afiya Pharmaceuticals 
Pvt. Ltd., 
Active 
Pharmaceutical 
Ingredient 
2 
Sodium starch 
glycolate 
Kniss Laboratories 
Super 
Disintegrant 
3 Crospovidone Kniss Laboratories 
Super 
Disintegrant 
4 
Croscarmellose 
sodium 
Kniss Laboratories 
Super 
Disintegrant 
5 Gelatin Microfine chemicals Binding Agent 
6 Talc Kniss Laboratories Glidant 
7 Magnesium stearate Kniss Laboratories Lubricant 
8 Lactose Kniss Laboratories Diluent 
9 Eudragit L-100 
Evonik India Pvt. 
Ltd., 
Enteric 
Polymer 
10 Eudragit S-100 
Evonik India Pvt. 
Ltd., 
Enteric 
Polymer 
11 Brilliant blue FCF 
Sai Mirra Innopharm 
Pvt. Ltd., 
Colourant 
12 Distilled water Lab chemicals 
Vehicle for 
Binder 
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Table No - 4: List of Equipments used 
S.No. Equipments / Instruments Manufacturer / Supplier 
1 Electronic weighing balance 
Asha Scientific Company, 
Mumbai 
2 Hot air oven MC Dalal, Chennai 
3 10 station compression machine Rimek India 
4 Vernier caliper Mitutoya, Japan 
5 Monsanto Hardness tester Standard steel, India 
6 Friabilator Electrolab, India 
7 pH Meter MC Dalal, Chennai 
8 Dissolution tester Campbell, India 
9 UV-Visible Spectrophotometer Schimadzu, India 
10 
Fourier Transform 
Infrared Spectrophotometer 
Schimadzu, India 
11 Disintegration Apparatus Electrolab, India 
12 Stability Chamber REMI CHM – 6 Plus 
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8.1. PREFORMUALTION STUDIES 
71
 
The Preformulation studies are conducted to establish the physicochemical 
characteristics of the drug and its compatibility with the various excipients utilised in 
the formulation. The Preformulation studies are necessary for obtaining stable, safe 
and effective dosage form. 
8.1.1. DRUG-EXCIPIENT COMPATIBILITY STUDY 
The Drug and the Excipients selected for the formulation are evaluated for 
physical and chemical compatibility studies. 
8.1.1.1. Physical Compatibility study 
The physical compatibility studies are conducted to provide valuable 
information to the formulator in selecting the appropriate excipients for the 
formulation. It was done by mixing the drug and excipients and kept at room 
temperature and at 40° C + 2° C and 75 % RH + 2 % RH. Any colour change of the 
physical mixture was observed visually. 
8.1.1.2. Chemical Compatibility study 
72, 73
 
Pure drug and Drug-Excipient mixtures were subjected to FT-IR to investigate 
the Drug-Excipient interactions. The Potassium bromide pellet method was utilized to 
obtain a sample which is placed in the sample cell of FT-IR Spectrophotometer. 
Potassium bromide pellet method 
A small amount of finely ground solid sample is intimately mixed with about 
100 times of its weight of powdered Potassium bromide. The finely ground mixture is 
then passed under high pressure in a press (at least 25,000 psi) to form a small pellet 
(about 1-2 mm thick and 1 cm in diameter). The resulting pellet is placed in the 
sample cell and the spectra were recorded. 
8.1.2. PREPARATION OF BUFFER SOLUTIONS 
63
 
Preparation of 0.1 N Hydrochloric acid 
 8.5 ml of conc. HCl is dissolved in few ml of distilled water and volume made 
up to 1000 ml with distilled water. 
Preparation of Phosphate buffer (pH-7.4) 
 50 ml of 0.2 M Potassium dihydrogen phosphate and 39.1 ml of 0.2 M NaOH 
is mixed and volume made up to 200 ml with distilled water. 
 0.2 M Potassium dihydrogen phosphate: 27.218 gram of Potassium 
dihydrogen phosphate is dissolved in few ml of distilled water and volume is made up 
to 1000 ml with distilled water. 
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 0.2 M NaOH: 8 g of NaOH is dissolved in few ml of distilled water, mixed 
well and volume made up to 1000 ml with distilled water. 
Preparation of Phosphate buffer (pH-4.5), Mixed 
 5.04 g of Disodium hydrogen phosphate and 3.01 g of Potassium dihydrogen 
phosphate is mixed and dissolved in 1000 ml of distilled water. Then the pH is 
adjusted using Glacial Acetic acid. 
8.1.3. CALIBRATION CURVE  
Calibration curve of Amitriptyline hydrochloride in 0.1 N Hydrochloric acid:  
100 mg of Amitriptyline hydrochloride is taken in 100 ml standard flask and it 
was dissolved in few ml of 0.1 N HCl, shaken well and made upto volume with 0.1 N 
HCl. From this, 10 ml of the solution was pipetted out into a 100 ml standard flask 
and volume make up is done by using 0.1 N HCl. 2 ml, 4 ml, 6 ml, 8 ml and 10 ml of 
the solutions were pipetted into separate standard flasks and made up to 100 ml using 
0.1 N HCl. The absorbance of the resulting solutions were measured at 239 nm using 
UV-Vis Spectrophotometer. Calibration curve was plotted in a graph using 
Concentration in x-axis and Absorbance in y-axis.  
Calibration curve of Amitriptyline hydrochloride in Phosphate buffer pH-4.5 
(mixed)  
100 mg of Amitriptyline hydrochloride is taken in 100 ml standard flask and it 
was dissolved in few ml of Phosphate buffer pH-4.5, shaken well and then the volume 
is made up with Phosphate buffer pH-4.5. From this, 10 ml of the solution was 
pipetted out into a 100 ml standard flask and volume make up is done by using 
Phosphate buffer pH-4.5. From this 2 ml, 4 ml, 6 ml, 8 ml and 10 ml of the solutions 
were pipetted into separate standard flasks and made up to 100 ml using Phosphate 
buffer pH-4.5. The absorbance of the resulting solutions were measured at 239 nm 
using UV-Vis Spectrophotometer. Calibration curve was plotted in a graph using 
Concentration in x-axis and Absorbance in a y-axis.  
Calibration curve of Amitriptyline Hydrochloride in Phosphate buffer pH-7.4  
100 mg of Amitriptyline Hydrochloride is taken in 100 ml standard flask and 
it was dissolved in few ml of Phosphate buffer pH-7.4, shaken well and then the 
volume is made up with Phosphate buffer pH-7.4. From this, 10 ml of the solution 
was pipetted out into a 100 ml standard flask and volume make up is done by using 
Phosphate buffer pH-7.4. From this 2 ml, 4 ml, 6 ml, 8 ml and 10 ml of the solutions 
were pipetted into separate standard flasks and made up to 100 ml using Phosphate 
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buffer pH-7.4. The absorbance of the resulting solutions were measured at 239 nm 
using UV-Vis Spectrophotometer. Calibration curve was plotted in a graph using 
Concentration in x-axis and Absorbance in y-axis. 
8.2. PRE-COMPRESSION PARAMETERS
 1, 2, 30, 63, 64.
 
 The Micromeritic properties are evaluated first before the Formulation 
process. The results of flow properties such as Angle of repose, Compressibility index 
and Hausner’s ratio give an idea about the selection of method of formulation of 
Tablets. The flow properties of powers are also critical for an efficient Tableting 
operation. A good flow of the powder or granules to be compressed is necessary to 
assure efficient mixing and acceptable weight uniformity for the compressed Tablets. 
8.2.1. Evaluation of Micromeritic properties of Drug, Granules and 
Compressible blend 
a) Bulk Density (ρb) 
An accurately weighed granules from each formula was slightly shaken to 
break any agglomerates formed and it was introduced into a measuring cylinder. The 
volume occupied by the granules was measured which gave bulk volume.  
The loose Bulk density of granules was determined using the following 
formula, 
                   
                           
                            
 
 
b) Tapped Density (ρt) 
An accurately weighed granules from each formula was slightly shaken to 
break any agglomerates formed and it was then introduced into a measuring cylinder. 
The measuring cylinder was tapped until no further change in volume was noted 
which gave the tapped volume. The Tapped densities of powder blends were 
determined by using the following formula, 
                    
                           
                                    
 
 
c) Hausner’s Ratio 
It indicates the flow properties of the granules and it is measured by the ratio 
of Tapped density to the Bulk density 
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Hausner’s ratio (H) = ρt / ρb 
Where, H is the Hausner’s ratio,  
 ρt is the tapped density of the granules and  
 ρb is the bulk density of the granules. 
 Hausner’s ratio is the measure of propensity to be compressed and also 
Interparticulate interactions / Interparticulate friction. 
d) Carr’s Index (or) Compressibility Index 
It is a simple index that can be determined on small quantities of granules. The 
compressibility indices of the formulation blends were determined using following 
formula. 
 
                                 
                            
              
      
 
Compressibility index is the measure of flow property of a powder. It is 
measured for determining the relative importance of Interparticulate interactions. It is 
expressed in Percentage. 
e) Angle of Repose 
 It is defined as the maximum angle possible between the surface of a pile of 
powder and the horizontal plane. It is determined by fixed funnel method. The powder 
mixtures were allowed to flow through the funnel fixed to a stand at definite height. It 
is useful for the determination of Interparticulate cohesion of powders. 
The angle of repose is then calculated by the formula mentioned below.  
Angle of Repose (θ) = tan-1 (h/r) 
Where, h = Height of the pile of powder (in cm)  
 r = Radius of pile of powder (in cm) 
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Table No - 5: Pre-compression parameters 
1, 64.
 
Flow Property 
Angle of Repose 
(in degrees) 
Compressibility 
Index (%) 
Hausner’s Ratio 
Excellent 25 – 30 < 10 1.00 - 1.11 
Good 31 – 35 11 – 15 1.12 - 1.18 
Fair 36 – 40 16 – 20 1.19 - 1.25 
Passable 41 – 45 21 – 25 1.26 - 1.34 
Poor 46 – 55 26 – 31 1.35 - 1.45 
Very Poor 56 – 65 32 – 37 1.46 - 1.59 
Very very Poor > 65 > 38 > 1.60 
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8.3. FORMULATION DEVELOPMENT 
2, 17, 25, 31, 47.
 
8.3.1. Formulation of Immediate-release Core Tablets of Amitriptyline 
hydrochloride 
 The Immediate-release Core Tablets of Amitriptyline hydrochloride were 
prepared using wet granulation method. The binder solution was prepared by 
dissolving Gelatin and Brilliant blue FCF (q.s) in water. The binder solution was 
mixed to the powder blend containing Drug, Diluent and Super Disintegrant. The 
coherent mass was passed in to sieve # 10. The granules were dried and passed 
through sieve # 22. Then the Lubricant and Glidant were added, mixed well and 
compressed into Tablets. 
Table No - 6: Formulation of Immediate-release Core Tablets of  
Amitriptyline hydrochloride 
S.No. Ingredients 
Quantity for 1 Tablet (mg) 
C-1 C-2 C-3 C-4 C-5 C-6 
1 Amitriptyline hydrochloride 10 10 10 10 10 10 
2 Sodium Starch Glycolate 4 8 - - - - 
3 Crospovidone - - 2 5 - - 
4 Croscarmellose Sodium - - - - 3 4 
5 Gelatin 3 3 3 3 3 3 
6 Talc 5 5 5 5 5 5 
7 Magnesium stearate 3 3 3 3 3 3 
8 Lactose 75 71 77 74 76 75 
9 Distilled water q.s q.s q.s q.s q.s q.s 
10 Brilliant blue FCF q.s q.s q.s q.s q.s q.s 
 
Average weight of each Tablet = 100 mg 
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Fig. No - 5: Flowchart for formulation of Amitriptyline hydrochloride Core 
Tablets 
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8.3.2. Formulation of Amitriptyline Hydrochloride Compression Coated Tablets 
 The Compression Coated Tablets of Amitriptyline hydrochloride is prepared 
by using pH-dependent polymers such as Eudragit L-100 and Eudragit S-100. It is 
prepared by Direct compression technique. Half-amount of the Coating layer/outer 
coat material is first filled in a die cavity then the Core Tablet is placed in the center 
of the cavity and then another half-amount of Coat is filled. Then it is compressed to 
produce Amitriptyline hydrochloride CCT. 
Table No - 7: Formulation of Amitriptyline hydrochloride  
Compression Coated Tablets 
S.No. Ingredients 
Quantity for 1 Tablet (mg) 
F-1 F-2 F-3 F-4 F-5 F-6 F-7 
1 
Optimised Core Tablet 
  (Formulation C-4) 
100 100 100 100 100 100 100 
2 Eudragit L-100 200 - 100 150 50 66.67 133.34 
3 Eudragit S-100 - 200 100 50 150 133.34 66.67 
4 Talc 17.5 17.5 17.5 17.5 17.5 17.5 17.5 
5 Magnesium stearate 10.5 10.5 10.5 10.5 10.5 10.5 10.5 
6 Lactose 122 122 122 122 122 122 122 
 
Average weight of each Tablet = 450 mg 
 
Table No - 8: Eudragit L-100 and Eudragit S-100 ratio in AMT CCT 
Formulation F – 1 F - 2 F – 3 F - 4 F – 5 F – 6 F - 7 
ED L-100 : 
ED S-100 
1:0 0:1 1:1 3:1 1:3 1:2 2:1 
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Fig. No - 6: Flowchart for formulation of Amitriptyline hydrochloride 
Compression coated Tablets 
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8.4. POST COMPRESSION STUDIES 
1, 2, 49, 53, 63, 64.
 
a) General appearance 
The general appearance of the Tablets from each formulation batch was 
observed. The general appearance parameters are Shape and Colour was evaluated 
visually.  
b) Uniformity of Weight 
Twenty Tablets were randomly selected and weighed individually. The 
average weight was also measured. The percentage deviation of Tablets was 
calculated and compared with standard specifications. 
Table No - 9: Uniformity of weight 
2
 
S.No. Average weight of Tablet % Deviation 
1 80 mg or less 10 
2 80 to 250 mg 7.5 
3 More than 250 mg 5 
 
c) Thickness and Diameter 
The Thickness and Diameter was measured to determine the uniformity of size 
and shape. Thickness and Diameter of the Tablets were measured using Vernier 
caliper. 
d) Hardness 
Hardness is defined as the force required for breaking a Tablet at diametric 
compression test and it is termed as “Tablet Crushing strength”. Hardness of the 
prepared formulations was determined using Monsanto Hardness Tester. It was 
expressed in kg/cm
2
.  
e) Friability 
Friability of the prepared formulations was determined by using Rochelle 
Friabilator. Pre-weighed sample of Tablets was placed in the Friabilator, which was 
then operated for 100 revolutions, Tablets were de-dusted and re-weighed. The 
Friability of the Tablets was calculated using the formula mention below, 
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f) Disintegration test for Amitriptyline Hydrochloride Core Tablets  
One tablet each was placed in each of the six tubes of the basket. The 
assembly was suspended in Phosphate buffer pH-7.4 maintained at a temperature of 
37
0
C + 0.5
0
C and the apparatus was operated. The time taken for complete 
disintegration of all tablets was noted. 
g) Drug Content Analysis 
49, 53
 
 The five tablets were randomly selected and ground. The powder equivalent to 
10 mg of Amitriptyline hydrochloride was transformed into the 100 ml standard flask, 
dissolved and the volume is made up with Phosphate buffer pH-7.4. Then it is filtered. 
From this 10 ml of filtrate is taken in a separate 100 ml standard flask and volume 
made with Phosphate buffer pH-7.4. The absorbance of the resulting solution was 
determined in UV-Visible Spectrophotometer using Phosphate buffer pH-7.4 as blank 
at a maximum wavelength about 239 nm.  
h) In-vitro drug release study 
i) For Amitriptyline hydrochloride Core Tablet 
74
 
  The in-vitro drug release study of Core tablets were done by using USP    
Type - II (Paddle) Dissolution apparatus under sink condition. 500 ml of Phosphate 
buffer pH – 7.4 was used as a dissolution medium. Stirring rate is maintained at 75 
RPM and the temperature is about 37ºC + 0.5ºC. The samples were withdrawn from 
the dissolution medium at various time intervals and the same volume of fresh 
medium is replaced for each and every sampling. Then the samples are analysed by 
UV-Visible Spectrophotometer using Phosphate buffer pH-7.4 as blank at a maximum 
wavelength about 239 nm.  
Ii) For Amitriptyline hydrochloride Compression Coated Tablet 
75, 76
 
For Colon targeted formulations the dissolution studies should performed 
under multimedia conditions i.e. at medium with different pH. According to USFDA 
guidelines the initial dissolution studies can be carried out at pH-1.2 and after a 
suitable time interval, a small amount of buffer can be added to raise the pH which 
will mimic the GIT conditions.    
 The Eudragit coated Amitriptyline hydrochloride Compression Coated Tablets 
were evaluated for the in-vitro drug release in Simulated GI fluid. The test is carried 
out using USP Type - II (Paddle) Dissolution apparatus under sink condition. 500 ml 
of Dissolution medium is taken in a cylindrical vessel. The content was rotated at 100 
RPM at 37ºC + 0.5ºC. The simulation of GI transit condition was achieved by altering 
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pH of the dissolution medium at different time intervals. The pH of the dissolution 
medium was kept 1.2 for 2 hours using  0.1 N HCl. Then KH2PO4 (1.7 g) and 
Na2HPO4.2H2O (2.2 g) were added to the dissolution medium, adjusting the pH to 4.5 
with 1.0 M NaOH, release study were continued for an additional 2 hours. After 4 
hours, the pH of the dissolution medium was adjusted to 7.4 with 0.1 N NaOH. The 
samples are withdrawn from the dissolution medium at various time intervals and the 
same volume of fresh medium is replaced for each and every sampling. Then the 
samples are analysed by UV-Visible Spectrophotometer using an appropriate blank 
solution for every samples at a maximum wavelength about 239 nm. 
  
 
 
          
 
 
 
 
 
 
 
 
 
 
Fig. No - 7: Flowchart for adjusting pH of dissolution medium for simulation of 
GI transit (Simulated Gastro-Intestinal Fluid)   
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.2H2O  
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by drop till pH 
becomes 4.5  
Volume of NaOH 
needed for adjusting 
pH to 4.5 is 39.6 ml. 
Add 0.1 N NaOH 
drop by drop till 
pH becomes 7.4 
Volume of NaOH needed for 
adjusting pH to 7.4 is 144.6 ml. 
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8.5. APPLICATION OF RELEASE RATE KINETICS TO DISSOLUTION 
DATA 
6, 31, 77.
 
Various models were tested for explaining the kinetics of drug release. To 
analyze the mechanism of the drug release rate kinetics of the dosage form, the 
obtained data were fitted into Zero order, First order, Higuchi, Hixson-Crowell release 
model and Korsmeyer-Peppas release model. 
1. Zero order equation 
The zero order release can be obtained by plotting cumulative % percentage 
drug release versus time. It is ideal for the formulation to have release profile of zero 
order to achieve pharmacological prolonged action. 
C=K0t 
  Where, K0 = Zero order constant 
      t = Time in hours 
2. First order equation 
The graph was plotted as log % cumulative drug remaining vs time in hours. 
Log C= log C0- Kt/2.303 
Where, C0 = Initial concentration of drug 
 K = First order 
  t = Time in hours 
3. Higuchi kinetics 
The graph was plotted with % cumulative drug release vs. square root of time 
Q = Kt
½
 
Where, K = constant reflecting design variable system (differential rate 
constant) 
  t = Time in hours 
4. Hixon and Crowell erosion equation 
To evaluate the drug release with changes in the surface area and the diameter 
of particles, the data were plotted using the Hixon and Crowell rate equation. The 
graph was plotted by cube root of % drug remaining vs. time in hours. 
Q0
1/3
 – Qt
1/3
 = KHCXt 
Where, Qt = amount of drug released in time t. 
Q0 = Initial Amount of drug 
         KHC = Rate constant for Hixon Crowell equation 
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5. Korsmeyer-Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug release Vs. log time. 
Mt/Mα = Kt
n
 
Where, Mt/Mα = Fraction of drug released at time t 
          t = Release time 
        K = Kinetics constant (Incorporating structural and geometric 
    characteristics of the formulation) 
         n = Diffusional exponent indicative of the mechanism of drug 
release. 
If slope (n) values is 0.45 or less, the release mechanism is fickian diffusion 
and if 0.45<n<0.89 it follows non-fickian model (anomalous model). The drug release 
follows zero order drug release and non-fickian case – II transport if the value is 0.89. 
For the values of n higher than 0.89, the mechanism of drug released is regarded as 
non-fickian super case II transport. The model is used to analyze the drug release of 
pharmaceutical polymeric dosage forms when the release mechanism is not known or 
more than one type of release is involved. 
8.6. STABILITY STUDIES 
3, 78.
 
Stability studies were conducted on the Optimised Amitriptyline 
hydrochloride Compression Coated Tablets. The stability was assessed with respect to 
their physical appearance, drug content and drug release by storing at ambient room 
temperature and 40ºC ± 2ºC maintained at RH 75% ± 5% for 6 months. The drug 
content and drug release of the Optimised formulation was evaluated biweekly using 
UV-Visible Spectrophotometer in at 239 nm. 
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9.1. PREFORMULATION STUDIES 
9.1.1. DRUG-EXCIPIENT COMPATIBILITY STUDY 
9.1.1.1. PHYSICAL COMPATIBILITY STUDY 
The drug-excipient compatibility study was conducted to reveal the excipient 
compatibility with the drug. The physical compatibility of drug and excipients were given in 
Table No. - 10.  
Table No. - 10: Physical compatibility study of Drug and Excipients 
Drug/ Excipient/  
Drug+ Excipient 
Description and Condition 
Initial 
At room temperature 
(in days) 
At 40° C + 2° C and 
75 % RH + 2 % RH 
(in days) 
10
th
 20
th
 30
th
 10
th
 20
th
 30
th
 
AMT White / almost white powder NC NC NC NC NC NC 
SSG White / off white powder NC NC NC NC NC NC 
CCS Grayish-white powder NC NC NC NC NC NC 
CP Creamy white powder NC NC NC NC NC NC 
Gelatin 
Faint yellow coloured 
Crystalline powder 
NC NC NC NC NC NC 
Talc White / off white powder NC NC NC NC NC NC 
Magnesium 
stearate (MS) 
White / off white powder NC NC NC NC NC NC 
Lactose Off white crystalline powder NC NC NC NC NC NC 
Eudragit L-100 White fine powder NC NC NC NC NC NC 
Eudragit S-100 White fine powder NC NC NC NC NC NC 
Brilliant blue 
FCF 
Reddish blue crystals NC NC NC NC NC NC 
AMT + SSG White / off white powder NC NC NC NC NC NC 
AMT + CCS Grayish-white powder NC NC NC NC NC NC 
AMT + CP Creamy white powder NC NC NC NC NC NC 
AMT + Gelatin 
Faint yellow coloured 
Crystalline powder 
NC NC NC NC NC NC 
AMT + Talc White / off white powder NC NC NC NC NC NC 
AMT + MS White / off white powder NC NC NC NC NC NC 
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AMT + Lactose Off white crystalline powder NC NC NC NC NC NC 
AMT + 
Eudragit L-100 
White fine powder NC NC NC NC NC NC 
AMT + 
Eudragit S-100 
White fine powder NC NC NC NC NC NC 
AMT + Brilliant 
blue FCF 
Sky blue coloured powder NC NC NC NC NC NC 
  
The physical compatibility study was performed visually. The study implies that the 
drug and excipients were physically compatible with each other, there was no change in 
physical description. The excipients which are selected for the formulation is Physically 
compatible with the drug. 
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9.1.1.2. CHEMICAL COMPATIBILITY STUDY 
The possible chemical interaction between the drug and the excipients used in the 
formulation was studied by FT-IR Spectroscopy. 
 
 
Fig. No. – 8: FT-IR spectra of Amitriptyline hydrochloride 
 
 
Table No. - 11: FT-IR Spectral interpretation of Amitriptyline hydrochloride 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
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Fig. No. – 9: FT-IR spectra of AMT + SSG 
 
 
Table No. - 12: FT-IR Spectral interpretation of AMT + SSG 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
 
Inference 
The peaks observed in the FT-IR spectra showed no disappearance of characteristic 
peaks of drug. This suggests that there was no interaction between the drug and Sodium 
Starch Glycolate. 
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Fig. No. – 10: FT-IR spectra of AMT + CCS 
 
 
Table No. - 13: FT-IR Spectral interpretation of AMT + CCS 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
 
Inference 
The peaks observed in the FT-IR spectra showed no disappearance of characteristic 
peaks of drug. This suggests that there was no interaction between the drug and 
Croscarmellose Sodium. 
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Fig. No. – 11: FT-IR spectra of AMT + CP 
 
 
Table No. - 14: FT-IR Spectral interpretation of AMT + CP 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
 
Inference 
The peaks observed in the FT-IR spectra showed no disappearance of characteristic 
peaks of drug. This suggests that there was no interaction between the drug and 
Crospovidone.  
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Fig. No. – 12: FT-IR spectra of AMT + ED L-100 
 
 
Table No. - 15: FT-IR Spectral interpretation of AMT + ED L-100 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
 
Inference 
The peaks observed in the FT-IR spectra showed no disappearance of characteristic 
peaks of drug. This suggests that there was no interaction between the drug and ED L-100. 
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Fig. No. – 13: FT-IR spectra of AMT + ED S-100 
 
 
Table No. - 16: FT-IR Spectral interpretation of AMT + ED S-100 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
 
Inference 
The peaks observed in the FT-IR spectra showed no disappearance of characteristic 
peaks of drug. This suggests that there was no interaction between the drug and ED S-100. 
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Fig. No. – 14: FT-IR spectra of formulation blend 
 
 
Table No. - 17: FT-IR Spectral interpretation of formulation blend 
 
Wave number (cm
-1
) Types of Vibration 
3062.13 Aromatic –CH stretching 
2924.21 Aliphatic –CH stretching 
1484.29 Aromatic C=C stretching 
2852.84 C-H (methyl group) stretching 
 
Inference 
The peaks observed in the FT-IR spectra showed no disappearance of characteristic 
peaks of drug. This suggests that there was no interaction between the drug and excipients 
used in the formulation. 
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9.2. CALIBRATION CURVE OF AMITRIPTYLINE HYDROCHLORIDE 
The Standard curve of Amitriptyline hydrochloride is prepared by Standard 
absorbance method using UV-Visible Spectrophotometric method. The absorbance of the 
AMT in various buffers: 0.1N HCl (pH-1.2), Phosphate buffer (pH-4.5) and Phosphate 
buffer (pH-7.4) was measured at a wavelength of 239 nm. The results were given below,  
Table No. - 18: Data for Calibration Curve of Amitriptyline hydrochloride 
S.No. 
Concentration 
( µg/ml ) 
Absorbance at 239 nm in three different pH 
pH – 1.2 pH – 4.5 pH – 7.4 
Abs. S.D. Abs. S.D. Abs. S.D. 
1 0 0 0 0 0 0 0 
2 2 0.092 0.0017 0.096 0.0112 0.102 0.0080 
3 4 0.177 0.0012 0.196 0.0167 0.196 0.0224 
4 6 0.279 0.0062 0.301 0.0108 0.284 0.0325 
5 8 0.365 0.0110 0.394 0.0277 0.371 0.0432 
6 10 0.444 0.0054 0.492 0.0249 0.468 0.0300 
(n=3) 
 
 
Fig. No. - 15: Standard curve of AMT in 0.1 N HCl (pH-1.2) 
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Fig. No. - 16: Standard curve of AMT in Phosphate buffer (pH-4.5) 
 
 
Fig. No. - 17: Standard curve of AMT in Phosphate buffer (pH-7.4) 
 
 The Standard curves of AMT in three different medium shows good linearity i.e. r
2
 
values are around 0.999. So it obeys Beer-Lambert’s law. 
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9.3. FOR AMT IMMEDIATE-RELEASE CORE TABLETS 
9.3.1. PRE-COMPRESSION STUDY 
The drug and the formulated blends are evaluated for Pre-compression parameters. 
The results are given in the Table No. – 19. 
 
Table No. - 19: Micromeritic properties of Drug, Powder blend 
Drug and 
Formulation 
Bulk 
Density* 
(g/cm
3
) 
Tapped 
Density* 
(g/cm
3
) 
Hausner’s 
ratio* 
Carr’s 
Index* 
(%) 
Angle of 
repose* 
AMT 0.349+0.0138 0.470+0.0328 1.35+0.1143 25.52+6.613 34º33’+1.1556 
C-1 0.518+0.0155 0.751+0.0357 1.45+0.1148 30.82+5.2250 34º06’+0.1266 
C-2 0.527+0.0167 0.870+0.0427 1.65+0.0719 39.30+2.6306 41º38’+2.3547 
C-3 0.451+0.0133 0.700+0.0329 1.55+0.0230 35.58+1.1027 38º38’+1.1178 
C-4 0.446+0.0133 0.611+0.0242 1.37+0.0513 27.01+2.6116 42º47’+2.1451 
C-5 0.427+0.0121 0.567+0.0208 1.32+0.0115 24.67+0.6351 38º34’+3.0571 
C-6 0462+0.0144 0.575+0.0002 1.25+0.0404 19.59+2.5115 42º53’+1.5841 
*Mean + S.D (n=3) 
 
The Bulk density of Amitriptyline hydrochloride and formulation blends ranges from 
0.349 to 0.527 g/cm
3
 and Tapped density ranges from 0.470 to 0.870 g/cm
3
. The 
Compressibility index of the drug and formulation blend ranges from 24.67 to 39.30 % and 
Hausner’s ratio ranges from 1.32 to 1.65. The angle of repose ranges from 34°06’ to 42°53’. 
The formulated blends were shows poor flow property. So wet granulation technique is used 
for preparing IR granules Amitriptyline hydrochloride. 
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Table No. – 20: Micromeritic properties of IR granules of AMT 
Formulation 
Bulk 
Density* 
(g/cm
3
) 
Tapped 
Density* 
(g/cm
3
) 
Hausner’s 
ratio* 
Carr’s 
Index* 
(%) 
Angle of 
repose* 
C-1 0.435+0.0144 0.563+0.0242 1.29+0.0133 22.65+0.7505 20º53’+0.4623 
C-2 0.439+0.0156 0.582+0.0266 1.33+0.0139 24.5+0.7910 28º06’+1.1720 
C-3 0.404+0.0118 0.489+0.0305 1.21+0.0493 17.32+3.1850 26º35’+1.1988 
C-4 0.401+0.0109 0.466+0.0150 1.16+0.0057 13.81+0.4157 25º37’+0.1967 
C-5 0.335+0.0103 0.396+0.0138 1.18+0.0057 15.4+0.3291 28º30’+1.1754 
C-6 0.319+0.0092 0.374+0.0127 1.18+0.0058 14.71+0.4330 30º46’+1.2683 
*Mean + S.D (n=3) 
 
The Bulk density of Amitriptyline Hydrochloride IR granules ranges from 0.319 to 
0.439 g/cm
3
 and Tapped density ranges from 0.374 to 0.582 g/cm
3
. The Compressibility 
index of the formulated granules ranges from 13.81 to 24.5 % and Hausner’s ratio ranges 
from 1.16 to 1.33. The angle of repose ranges from 20°53’ to 30°46’. The formulated IR 
granules of AMT were shows good flow property.  
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The Micromeritic properties of IR granules after mixing with flow promoters such as 
glidant and lubricant were evaluated. The results are showed below, 
 
Table No. - 21: Micromeritic properties of IR granules with Glidant and Lubricant 
(Compressible blend) 
Formulation 
Bulk 
Density* 
(g/cm
3
) 
Tapped 
Density* 
(g/cm
3
) 
Hausner’s 
ratio* 
Carr’s Index* 
(%) 
Angle of 
repose* 
C-1 0.545+0.0202 0.596+0.0000 1.09+0.0404 8.50+3.3890 18º09’+0.5635 
C-2 0.574+0.0248 0.693+0.0346 1.21+0.0577 17.04+3.8709 22º58’+1.8756 
C-3 0.501+0.0173 0.571+0.0225 1.14+0.0057 12.24+0.04387 24º45’+1.6122 
C-4 0.466+0.0133 0.520+0.0167 1.12+0.0057 10.37+0.3406 22º45’+1.0013 
C-5 0.457+0.0285 0.509+0.0202 1.11+0.0379 10.31+3.1315 27º37’+0.0602 
C-6 0.434+0.0150 0.471+0.0173 1.09+0.0379 7.88+3.2651 26º43’+0.5954 
*Mean + S.D (n=3) 
 
The Bulk density of Compressible blend ranges from 0.434 to 0.574 g/cm
3
 and 
Tapped density ranges from 0.471 to 0.693 g/cm
3
. The Compressibility index ranges from 
7.88 to 17.04 % and Hausner’s ratio ranges from 1.09 to 1.21. The angle of repose ranges 
from 18°09’ to 27°37’. The formulated compressible blend shows excellent flow property. 
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9.3.2. POST COMPRESSION STUDY 
1. UNIFORMITY OF WEIGHT 
The uniformity of weight of the formulated Tablets is given in Table No. – 22. 
Table No. - 22: Uniformity of weight of formulated Core Tablets 
Formulation Uniformity of weight* (mg) 
C-1 104.40+1.9285 
C-2 102.00+3.0709 
C-3 100.90+3.8805 
C-4 101.90+2.4426 
C-5 99.81+3.3107 
C-6 99.70+3.0675 
*Mean ±S.D (n=20) 
The formulated Tablet complies with the test for uniformity of weight. 
 
2. THICKNESS AND DIAMETER 
The Thickness and Diameter of the formulated Tablets is given in Table No. – 23. 
Table No. - 23: Thickness and Diameter of the formulated Core Tablets 
Formulation Thickness* (mm) Diameter* (mm) 
C-1 2+0 6+0 
C-2 2+0 6+0 
C-3 2+0 6+0 
C-4 2+0 6+0 
C-5 2+0 6+0 
C-6 2+0 6+0 
*MEAN±S.D (n=5) 
The formulated Tablets have uniform Thickness and Diameter. 
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3. HARDNESS 
The Hardness of the formulated Tablets is given in the Table No. - 24  
Table No. - 24: Hardness of the formulated Core Tablets 
Formulation Hardness* (kg/cm
2
) 
C-1 2.8+0.2738 
C-2 2.7+0.2738 
C-3 2.5+0.3536 
C-4 2.1+0.2236 
C-5 2.1+0.2236 
C-6 1.3+0.2739 
*MEAN±S.D (n=5) 
The Hardness of the tablets was found to be between 1.3 kg/cm
2
 and 2.8 kg/cm
2
. 
 
4. FRIABILITY 
The Friability of the formulated Tablets is given in the Table No. - 25 
Table No. - 25: % Friability of the formulated Core Tablets 
Formulation % Friability* (%) 
C-1 0.419+0.0245 
C-2 0.484+0.2014 
C-3 0.536+0.0326 
C-4 0.561+0.1245 
C-5 0.583+0.0278 
C-6 0.753+0.0125 
*Mean ±S.D (n=3) 
 
The percentage friability of all the formulation was within the Pharmacopoeial 
limits. 
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5. DISINTEGRATION TIME 
The disintegration time of the IR Core Tablets is given in the Table No. – 26. 
Table No. - 26: Disintegration time of the IR Core Tablets of AMT 
Formulation 
Disintegration time*  
(minutes : seconds) 
C-1 9:10+0.0154 
C-2 8:42+0.0162 
C-3 0:34+0.0142 
C-4 0:28+0.0096 
C-5 1:21+0.0101 
C-6 0:56+0.0216 
*Mean ±S.D (n=3) 
The Disintegration time of formulated Amitriptyline hydrochloride Immediate-
release Core Tablets ranges from 28 seconds to 9 minutes and 10 seconds. The 
Disintegration time of AMT Core Tablet (C-4) containing Crospovidone (5%) as super 
disintegrant was disintegrate quickly and the C-4 formulation is chosen for the Compression 
coating. All the formulation complies with the official standards. 
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6. DRUG CONTENT 
The Drug content of the formulated IR Tablets is given in the Table No. – 27. 
Table No. - 27: Drug content of the formulated Core Tablets 
Formulation % Drug content* (% w/w) 
C-1 99.80+0.0093 
C-2 104.30+0.0102 
C-3 95.04+0.0256 
C-4 95.91+0.0077 
C-5 98.50+0.0084 
C-6 98.90+0.0103 
*Mean ±S.D (n=3) 
The percentage drug content of all the formulations ranges from 95.04 % w/w to 
104.30 % w/w. It complies with the official monograph of the drug.  
 
 
Fig. No. - 18: Drug content of the formulated Core Tablets 
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7. In-vitro DRUG RELEASE STUDY 
The in-vitro drug release study of Immediate-release formulations of AMT is given 
in the Table No. – 28. 
Table No. - 28: In-vitro drug release study of Immediate-release formulation of AMT. 
Time 
(minutes) 
Percentage drug release (%) 
C-1 C-2 C-3 C-4 C-5 C-6 
0 0 0 0 0 0 0 
1 - - 5.05 27.63 - - 
2 - - 9.63 50.43 - - 
3 - - 30.24 78.04 - - 
4 - - 51.06 94.55 - - 
5 9.22 17.07 72.08 102.26 2.74 33.27 
6 - - 90.99 - - - 
7 - - 100.94 - - - 
10 20.03 25.58 - - 7.13 57.76 
15 28.95 38.30 - - 29.13 84.53 
20 44.47 51.04 - - 46.99 94.16 
25 60.04 61.99 - - 51.92 101.66 
30 67.14 74.97 - - 67.78 - 
35 76.51 84.04 - - 103.65 - 
40 81.56 91.09 - - - - 
45 91.07 96.09 - - - - 
50 98.45 105.35 - - - - 
55 103.70 - - - - - 
60 - - - - - - 
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Fig. No. - 19: In-vitro drug release study of Immediate-release AMT Core Tablets 
 
 
Fig. No. - 20: In-vitro dissolution of Immediate-release AMT Core Tablets 
 
From the in-vitro drug release study the formulation C-4 quickly releases the drug 
(within 5 minutes). So, formulation C-4 was selected for Compression coating. 
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9.4. FOR AMT COMPRESSION COATED TABLETS 
9.4.1. PRE-COMPRESSION STUDY 
The formulated Coating material blends are evaluated for Pre-compression 
parameters. The results are given in the Table No. – 29. 
 
Table No. - 29: Micromeritic properties of Coating material 
Formulation 
Bulk 
Density* 
(g/cm
3
) 
Tapped 
Density* 
(g/cm
3
) 
Hausner’s 
ratio* 
Carr’s Index* 
(%) 
Angle of 
repose* 
F-1 0.579+0.0167 0.677+0.0231 1.17+0.0115 14.56+0.4330 26°13’+0.0327 
F-2 0.537+0.0075 0.643+0.0109 1.19+0.0231 16.57+1.3159 33°41’+0.0032 
F-3 0.547+0.0135 0.637+0.0219 1.16+0.0208 14.14+1.4949 28°39’+0.0237 
F-4 0.528+0.0150 0.637+0.0109 1.21+0.0305 16.96+2.0359 29°01’+0.0451 
F-5 0.515+0.0125 0.593+0.0098 1.15+0.0115 13.05+1.0993 33°24’+0.0301 
F-6 0.525+0.0130 0.599+0.5996 1.14+0.0300 12.42+2.3744 34°11’+0.0756 
F-7 0.522+0.0078 0.590+0.0160 1.13+0.0173 11.45+1.4687 32°26’+0.0694 
*Mean + S.D (n=3) 
The Bulk density of formulated Coating material blends ranges from 0.515 to     
0.579 g/cm
3
 and Tapped density ranges from 0.590 to 0.677 g/cm
3
. The Compressibility 
index of the Coating material blend ranges from 11.45 % to 16.96 % and Hausner’s ratio 
ranges from 1.13 to 1.21. The angle of repose ranges from 26°13’ to 34°11’. The formulated 
Coating material blends were shows good flow property. So, Direct compression technique 
is selected for Compression coating of AMT Core tablets. 
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9.4.2. POST COMPRESSION STUDY 
1. UNIFORMITY OF WEIGHT 
The uniformity of weight of the formulated Tablets is given in Table No. – 30. 
Table No. - 30: Uniformity of weight of formulated AMT CCT 
Formulation Uniformity of weight* (mg) 
F-1 447.92+4.3360 
F-2 448.28+4.0259 
F-3 448.38+4.1496 
F-4 449.78+3.9783 
F-5 442.43+4.3741 
F-6 441.93+4.5392 
F-7 444.28+4.4534 
*Mean ±S.D (n=20) 
The formulated Tablet complies with the test for uniformity of weight. 
 
2. THICKNESS AND DIAMETER 
The Thickness and Diameter of the formulated Tablets is given in Table No. – 31. 
Table No. - 31: Thickness and Diameter of the formulated AMT CCT 
Formulation Thickness* (mm) Diameter* (mm) 
F-1 4+0 10+0 
F-2 4+0 10+0 
F-3 4+0 10+0 
F-4 4+0 10+0 
F-5 4+0 10+0 
F-6 4+0 10+0 
F-7 4+0 10+0 
*MEAN±S.D (n=5) 
The formulated Tablets have uniform Thickness and Diameter. 
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3. HARDNESS 
The hardness of the formulated Tablets is given in the Table No. – 32. 
Table No. - 32: Hardness of the formulated AMT CCT 
Formulation Hardness* (kg/cm
2
) 
F-1 3.2+0.2739 
F-2 5.3+0.4472 
F-3 5.5+0.5000 
F-4 4.3+0.2739 
F-5 4.3+0.2180 
F-6 4.4+0.4183 
F-7 4.5+0.3536 
*MEAN±S.D (n=5) 
The Hardness of the tablets was found to be between 3.2 kg/cm
2
 and 5.5 kg/cm
2
. 
 
4. FRIABILITY 
The Friability of the formulated Tablets is given in the Table No. – 33. 
Table No. - 33: % Friability of the formulated AMT CCT 
Formulation % Friability* (%) 
F-1 0.630+0.0824 
F-2 0.404+0.0421 
F-3 0.373+0.0174 
F-4 0.503+0.0146 
F-5 0.544+0.0186 
F-6 0.534+0.0365 
F-7 0.586+0.0153 
*Mean ±S.D (n=3) 
 
The percentage friability of all the formulation was within the Pharmacopoeial 
limits. 
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5. DRUG CONTENT 
The Drug content of the formulated Compression coated Tablets of Amitriptyline 
hydrochloride is given in the Table No. – 34. 
Table No. - 34: Drug content of the formulated AMT CCT 
Formulation % Drug content* (% w/w) 
F-1 96.60+0.0514 
F-2 100.90+0.0123 
F-3 100.50+0.0035 
F-4 94.20+0.0084 
F-5 95.04+0.0426 
F-6 97.06+0.0512 
F-7 100.2+0.0225 
*Mean ±S.D (n=3) 
The percentage drug content of all the formulations ranges from 94.20 % w/w to 
100.90 % w/w. It complies with the official monograph of the drug. 
 
 
Fig. No. - 21: Drug content of the formulated AMT CCT 
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6. In-vitro DRUG RELEASE STUDY 
The in-vitro drug release study of Compression coated formulations of Amitriptyline 
hydrochloride is given in the Table No. – 35. 
Table No. - 35: In-vitro drug release study of AMT CCT 
Time 
(hours) 
Percentage drug release (%) 
F-1 F-2 F-3 F-4 F-5 F-6 F-7 
0 0 0 0 0 0 0 0 
0.5 14.18 11.49 13.73 16.99 3.40 16.39 7.08 
1 16.70 13.79 13.87 21.93 6.35 21.17 9.35 
1.5 19.25 13.93 16.19 24.85 8.15 23.63 9.45 
2 19.44 16.25 18.64 24.73 9.39 23.86 11.83 
2.25 26.85 25.59 34.47 39.28 21.69 31.27 21.28 
2.5 31.37 27.97 36.93 39.63 24.22 31.55 23.63 
2.75 38.67 34.75 41.67 44.69 26.14 34.05 30.42 
3 43.59 37.20 46.34 47.38 29.82 38.77 32.85 
3.25 50.81 37.53 49.01 54.79 32.41 43.65 33.30 
3.5 51.26 40.11 53.77 57.57 33.84 48.47 35.61 
3.75 56.18 49.13 54.22 60.37 36.44 51.22 38.08 
4 58.91 55.99 54.69 60.90 36.76 51.66 42.84 
4.02 - - - - 48.76 - - 
4.03 - - - - 71.19 - - 
4.05 - - - - 95.43 - - 
4.07 - - - - 98.18 - - 
4.08 96.61 92.08 93.06 90.11 110.73 89.52 95.11 
4.17 - - 105.57 100.19 - 96.18 101.31 
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Fig. No. - 22: In-vitro drug release study of AMT CCT 
When comparing the % drug release of all formulations, it was observed that 
formulation F-5 gave the drug release - 9.39 % in first 2 hours in pH - 1.2 followed by drug 
release – 36.76 % in next 2 hours in pH - 4.5 and rest of the drug was released quickly in  
pH - 7.4. So, the formulation F-5 containing Eudragit L-100 and Eudragit S-100 in the ratio 
of 1:3 retains the maximum amount of drug in first 4 hours in the pH - 1.2 and pH – 4.5 
when compared to other formulations. So, the Formulation F-5 is considered as a optimized 
formulation for the Colon targeted Amitriptyline hydrochloride Compression Coated 
Tablets (AMT CCT). 
Amol Paharia et al., formulated Eudragit-coated Pectin Microspheres of                   
5-Fluorouracil for Colon targeting. The drug release pattern obtained for the present study of 
AMT CCT is quite similar with this research work, in both study there are some amount of 
drug released in first 4 hours in the pH -1.2 and pH – 4.5 and then remaining amount of the 
drug was released in pH-7.4.
76.
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9.5. RELEASE KINETICS AND MECHANISM 
 The formulated Delayed release dosage form provides the burst release after 4 hours 
when the pH of the medium becomes 7.4. The kinetics of drug release for the optimized 
AMT CCT was helpful to know whether the maximum amount drug reaches to the Colon 
from the formulated CCT which pass through the upper part of GIT in a controlled manner 
or not (i.e. the drug release in first 4 hours). The release kinetics of optimized AMT CCT 
was shown in the Table No. – 36. 
Table No. - 36: Drug release kinetics of optimized AMT CCT 
Time 
(hours) 
% cum. 
Drug 
release 
% cum. 
Drug 
remaining 
Log % 
cum. 
Drug 
remaining 
Square 
root of 
time 
Log 
time 
Log % 
cum. 
Drug 
release 
Cube root 
of % drug 
remaining 
0 0 100 2 0 α α 4.6416 
0.5 3.40 96.60 1.9850 0.7071 -0.3010 0.5315 4.5884 
1 6.35 93.65 1.9715 1 0 0.8028 4.5412 
1.5 8.15 91.85 1.9631 1.2247 0.1761 0.9112 4.5119 
2 9.39 90.61 1.9572 1.4142 0.3010 0.9727 4.4915 
2.25 21.69 78.31 1.8938 1.5 0.3522 1.3363 4.2783 
2.5 24.22 75.78 1.8796 1.5811 0.3979 1.3842 4.2317 
2.75 26.14 73.86 1.8684 1.6583 0.4393 1.4173 4.1957 
3 29.82 70.18 1.8462 1.7321 0.4771 1.4745 4.1248 
3.25 32.41 67.59 1.8299 1.8028 0.5119 1.5107 4.0734 
3.5 33.84 66.16 1.8206 1.8708 0.5441 1.5294 4.0445 
3.75 36.44 63.56 1.8032 1.9365 0.5740 1.5616 3.9908 
4 36.76 63.24 1.8010 2 0.6021 1.5654 3.9841 
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Fig. No - 23: Zero order release kinetics 
 
 
Fig. No -24: First order release kinetics 
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Fig. No. - 25: Higuchi diffusion kinetics 
 
 
Fig. No. - 26: Hixon-crowell release kinetics 
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Fig. No. - 27: Korsmeyer-Peppas release kinetics 
 
 
 The AMT CCT follows Zero order release kinetics until it reaches pH-7.4 which 
mimics the Colonic condition, in which regression value was 0.948.  
 The “n‟ value of Korsmeyer-peppas equation was found to be 1.2698. From this it 
was concluded that the drug release follows non-fickian diffusion. 
77.
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9.6. STABILITY STUDIES 
 The stability studies of the optimized formulations are done at ambient room 
temperature and 40ºC ± 2ºC maintained at RH 75% ± 5% for 45 days. 
 There was no significant difference in the physical appearance of the formulation. 
Table No. - 37: Stability study of AMT CCT – Optimised formulation 
Sample 
withdrawal 
period 
Drug content (% w/w) 
% drug release (at the  
end of 4.08 hours) (%) 
At Ambient 
temperature 
40ºC ± 2ºC 
and 75% ± 5% 
RH 
At Ambient 
temperature 
40ºC ± 2ºC 
and 75% ± 5% 
RH 
0
th
 day 96.21 95.21 102.34 98.24 
15
th
 day 97.02 96.59 98.91 99.50 
30
th
 day 96.55 96.65 99.26 98.99 
45
th
 day 97.52 97.29 98.76 99.20 
 
 
Fig. No. - 28: Stability study of AMT CCT – Drug content analysis 
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Fig. No. - 29: Stability study of AMT CCT – Drug release study 
 
There was no significant difference in the results of drug content analysis and the         
in-vitro drug release studies of the optimized formulation. This shows that the formulations 
remained stable during the process of storage.  
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The present work involves the formulation development and in-vitro evaluation of Colon 
targeted Compression Coated Tablets containing Amitriptyline hydrochloride, in which the core 
Tablets are Immediate-release formulation which is coated with pH-dependent polymers 
Eudragit L-100 and Eudragit S-100 in different ratios. This is designed for the treatment of 
Irritable Bowel Syndrome.  
 
The polymer and other excipients were selected based on the satisfying results produced 
during Drug-Excipient compatibility studies to develop the final formulation. 
  
The Calibration curves of Amitriptyline Hydrochloride were constructed at three different 
pH (1.2, 4.5 and 7.4). 
 
Totally six formulations of Immediate-release AMT Core Tablets were formulated using 
wet granulation method with SSG (4 % and 8 %), CCS (3 % and 4 %) and Crospovidone (2 % 
and 5%). 
 
Immediate-release Core Tablets of AMT were prepared by Wet granulation method 
because of the poor flow property of the blends. 
The formulated IR granules of AMT were evaluated for Micromeritic properties which 
showed good flow property.  
 
The formulated Tablets were found to be within the limits with respect to Weight 
uniformity, Hardness, Thickness, Diameter and Friability. 
  
The Drug content of the formulated Tablets was found to be within the Pharmacopoeial 
limits (100 % + 10 %). 
 
The AMT Immediate-release Core Tablet (Formulation C-4) containing CrosPovidone    
5 % was found to disintegrate quickly (D.T = 28 seconds). 
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The in-vitro dissolution studies of the formulated AMT Core Tablets were performed 
using USP Type - II dissolution apparatus. From the formulated batches, the formulation C-4 
releases the drug as quick as other formulations (within 5 minutes). 
 
Based on the Disintegration and in-vitro release studies of AMT Immediate-release Core 
Tablets, formulation C-4 was optimized and selected for Compression coating. 
 
The outer coat contains pH-dependent enteric polymers such as Eudragit L-100 and 
Eudragit S-100. For the formulated coating material blend Micromeritic properties was evaluated 
and shows good flow. So, the Compression coating of optimized AMT Core Tablets was done by 
Direct compression technique. 
  
Totally 7 batches of Amitriptyline hydrochloride Compression Coated Tablets (AMT 
CCT) were prepared by different ratios of Eudragit L-100 and Eudragit S-100. 
 
The formulated AMT CCT was found to be within limits with respect to Weight 
uniformity, Hardness, Thickness, Diameter and Friability. 
 
 The drug content of the AMT CCT were estimated and found to be within 
Pharmacopoeial limits (100 % + 10 %). 
 
The in-vitro dissolution studies of the formulated AMT CCT were performed using USP 
Type  - II dissolution apparatus in three different pH conditions. From the formulated batches, 
the % drug release for the formulation F-5 was found to be 9.39 % at pH-1.2 in first 2 hours, 
36.76 % at pH-4.5 in next 2 hours and then 98.18 % in 4.07 hours. The formulation F-5 retains 
the maximum amount of drug in first 4 hours in two different pH (1.2 and 4.5) which mimic the 
pH of the upper GIT, then the other formulations (F-1, F-2, F-3, F-4, F-6 and F-7). 
 
Based on the in-vitro release studies of AMT CCT, formulation F-5 (formulation 
containing Eudragit L-100 and Eudragit S-100 ratio of 1:3) was optimised. 
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The release kinetics of the AMT CCT followed Zero order kinetics until it reaches the 
pH-7.4 which mimic Colonic condition. From the “n‟ value of Korsmeyer-peppas equation, the 
AMT CCT follows a non-fickian diffusion.  
 
Stability studies for the optimized AMT CCT was performed by storing the Tablets at 
ambient room temperature and 40ºC ± 2ºC maintained at RH 75% ± 5% for 45 days. There was 
no significant differences produced in physical appearance, drug content and % drug release, this 
shows that the formulation remains stable during the storage. 
 
FUTURE PLAN:  
 Scale up studies of the optimized formulation 
 In-vivo studies and IVIVC. 
 Bioequivalence studies with marketed products 
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